

Refund of common stock from IPO

Issuance of common stock - warrants exercised

Balance June 30, 2024

See accompanying notes to the unaudited condensed financial statements.

Table of Contents

Automomix Medical, Inc. Condensed Statements of Cash Flows (Unaudited)

Three Months Ended June 30, (in thousands)

2024

2023

Cash Flows from Operating Activities:

Net loss

Adjustments to reconcile net loss to net cash used in operating activities:

Stock-based compensation

Depreciation and amortization expense

Changes in operating assets - decrease/increase:

Other current assets

Changes in operating liabilities - (decrease)/increase:

Accounts payable

Accrued expenses

Net cash used in operating activities

Cash Flows from Investing Activities:

Purchase of property and equipment

Net cash used in investing activities

Cash Flows from Financing Activities:

Issuance of common stock

Payment of offering costs

Net cash provided by financing activities

Net change in cash and cash equivalents

Cash and cash equivalents, at beginning of period

Cash and cash equivalents, at end of period

Supplemental cash flow disclosures:

Non-cash financing activities:

Cashless exercise of warrants

See accompanying notes to the unaudited condensed financial statements.

Table of Contents

Automomix Medical, Inc. Notes to the Unaudited Condensed Financial Statements

Note 1

Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies

Description of the Business

Automomix Medical, Inc. (

is a medical device company organized as a Delaware corporation on June 10, 2014. The Company is a pre-revenue, clinical stage life sciences company focused on advancing innovative technologies for sensing and treating disorders relating to the peripheral nervous system.

Liquidity and Going Concern

The Company's financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company is an early-stage company that is subject to all the risks associated with early-stage and emerging growth companies and has incurred losses since inception.

For the three months ended June 30, 2024 and 2023, the Company incurred net losses of \$2.7 million and \$0.9 million, respectively, and had net cash flows used in operating activities of \$1.9 million and \$0.7A million, respectively. The Company had no revenues for the three months ended June 30, 2024 and 2023, respectively, and an accumulated deficit of \$41.7A million, working capital of \$6.3 million and cash of \$6.8 million as of June 30, 2024. The Company does not expect to generate positive cash flows from operating activities in the near future.

The Company estimates its current cash resources are sufficient to fund its operations into but not beyond the second calendar quarter of 2025. The Company recognizes it will need to raise additional capital to continue to execute its business plan, including obtaining regulatory clearance for its products currently under development and commercializing and generating revenues from products under development. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company. A failure to raise sufficient capital, generate sufficient product revenues, control expenditures and regulatory matters, among other factors, will adversely impact the Company's ability to meet its financial obligations as they become due and payable and to achieve its intended business objectives. If the Company is unable to raise sufficient additional funds, it will have to scale back its operations.

These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued. The accompanying condensed financial statements have been prepared on a going concern basis and do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Basis of Presentation

The accompanying condensed interim financial statements are unaudited. These unaudited condensed interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC) for interim financial information. Accordingly, they do not include all the information and notes required by generally accepted accounting principles in the United States of America (GAAP) for complete financial statements. The Company's fiscal year end is March 31st. These unaudited condensed interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended March 31, 2024 as found in the Annual Report in our Form 10-K filed with the SEC on May 31, 2024. In the opinion of management, the unaudited condensed interim financial statements reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company's financial position, results of operations and cash flows for the quarterly and year-to-date periods, as applicable. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The March 31, 2024 audited condensed balance sheet included herein was derived from the audited financial statements, but does not include all disclosures, including notes, required by GAAP for complete financial statements.

Table of Contents

Use of Estimates in Financial Statement Presentation

The preparation of these unaudited condensed interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include work performed but not yet billed by contract manufacturers, engineers and research organizations and the valuation of equity related instruments. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid accounts with original maturities of three months or less at the date of acquisition to be cash equivalents. Periodically, the Company may carry cash balances at financial institutions in excess of the federally insured limit of \$250,000. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.

Offering Costs

Offering costs consist of professional costs incurred through the balance sheet date that are direct and incremental related to the Company's initial public offering ("IPO"). These costs, together with the selling agent fees, were reclassified to additional paid-in capital upon completion of the Company's IPO on January 26, 2024. Costs associated with salaries and other period costs were expensed as incurred.

During the three months ended June 30, 2024 and 2023, the Company paid \$0A and \$0.1 million, respectively, of offering costs related to its IPO.

Property and Equipment

Property and equipment (comprised of computer and IT equipment) are stated at historical cost and depreciated on a straight-line basis over their estimated useful lives, generally three years. Upon disposition of the assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations.

Convertible Notes

The Company evaluates embedded redemption, conversion and other features within its debt to determine whether any embedded features should be bifurcated from the host instrument and accounted for as a derivative at fair value, with changes in fair value recorded in the condensed statements of operations.

The Company's debt is carried on the condensed balance sheets on a historical cost basis net of unamortized discounts and premiums because the Company has not elected the fair value option of accounting. Costs associated with acquiring debt, including detachable warrants issued in connection with the financing, are capitalized as a debt discount. The debt discount is presented in the condensed balance sheets as a direct deduction from the carrying amount of the debt liability. The costs are amortized over the estimated contractual life of the related debt instrument using the effective interest method and are included in interest expense in the condensed statements of operations.

If the Company incurs costs associated with its convertible notes, in advance of the receipt of proceeds, the Company will record a deferred asset. Upon receipt of proceeds the Company will reclassify the deferred asset as a direct deduction from the carrying amount, as described above.

In addition, since the instruments included a substantive conversion feature as of time of issuance, the issuance of equity securities to settle the outstanding notes with the conversion were accounted for as a contractual conversion with no gain or loss recognized related to the equity securities issued to settle the instrument.

Table of Contents

Fair Value of Financial Instruments

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a three-level valuation hierarchy for disclosures of fair value measurements, defined as follows:

Level 1

inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets

Level 2

inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instrument

Level 3

inputs to the valuation methodology are unobservable and significant to the fair value and require significant judgment and estimation.

Financial assets and financial liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. While the Company believes that its valuation methods are appropriate, the Company recognizes that the use of different methodologies or assumptions to determine the fair value could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values are the probability weighting of the different settlement outcomes used.

The Company did not have any assets or liabilities measured at fair value as of or during the three-month period ending June 30, 2024 and March 31, 2024. There were no any transfers into or out of Level 3 as of June 30, 2024 and March 31, 2024.

As of June 30, 2024, the Company determined that the estimated fair value of debt was approximately \$1.0 million. The fair value of debt was estimated using market rates the Company believes would be available for similar types of financial instruments and represents a Level 2 measurement.

The carrying value of short-term instruments, including cash, accounts payable and accrued expenses, approximate fair value due to the relatively short period to maturity for these instruments.

Related Parties

The Company follows Accounting Standards Codification ("ASC") 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions. See further discussion in Note 5 below on this matter.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. As of June 30, 2024 and March 31, 2024 the Company determined a full valuation allowance was required to offset its deferred tax assets as a result of recurring operating losses.

The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740-10 which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than not to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates. As of June 30, 2024 and March 31, 2024 the Company had no uncertain tax positions.

The Company does not expect to pay any significant federal, state, or foreign income taxes in our fiscal year 2025 (ending March 31, 2025) as a result of the losses recorded during the three months ended June 30, 2024A and the additional losses expected for the remainder of our fiscal year 2025A and cumulative net operating loss carryforwards. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is more likely than not that some component or all of the benefits of deferred tax assets will not be realized.

Table of Contents

The Company recorded no income tax provision for the three months ended June 30, 2024 and 2023, respectively. The effective tax rate for the three months ended June 30, 2024 and 2023A is zero.

The Company estimates its annual effective tax rate at the end of each quarterly period. Jurisdictions with a projected loss for the year where no tax benefit can be recognized due to the valuation allowance could result in a higher or lower effective tax rate during a particular quarter depending on the mix and timing of actual earnings versus annual projections.

Stock-based Compensation

Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. For awards with a performance condition, compensation expense is recognized over the requisite service period if it is probable that the performance condition will be satisfied. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the Company had paid cash for the goods or services. The Company estimates the fair value of options and equity classified warrants granted using an options pricing model. Expense is recognized within general and administrative expenses and forfeitures are recognized as they are incurred.

Warrants

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant's specific terms and applicable authoritative guidance in FASB ASC 480, Distinguishing Liabilities from Equity (ASC 480A) and ASC 815, Derivatives and Hedging (ASC 815A). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company's own ordinary shares and whether the warrant holders could potentially require cash settlement in a circumstance outside of the Company's control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing model or a Monte Carlo simulation.

Loss Per Common Share

Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. Generally, the Company's outstanding warrants are non-participating securities as they are not entitled to non-forfeitable rights to dividends or dividend equivalents during the vesting term and have no obligation to fund losses.

However, the warrants described in Note 5A are participating securities as they receive a right to dividends, but they are not obligated to fund losses. In periods of loss, since no income is allocated to these securities, the Company's use of the treasury stock method derives the same result. The dilutive effect of convertible securities is calculated using the if-converted method. Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted calculation for the entire period being presented.

For the three months ended June 30, 2024 and 2023, dilutive securities that were not included in the calculations of the loss per common share because they would be anti-dilutive included the following:

June 30, 2024

2023

Equity based warrants to purchase common shares

Convertible Notes - common shares

Convertible Notes - equity-based warrants to purchase common shares

Stock options granted under Company's incentive plan

Total potentially dilutive securities

Research and Development Costs

Research and development costs are expensed as incurred.

Advertising

It is our policy to expense advertising costs as incurred. Advertising expenses are included within general and administrative expenses within the statement of operations. For the three months ended June 30, 2024 and 2023, the Company recorded less than \$0.1A million and \$0.1 million, respectively.

Fair Value of Common Stock

Prior to establishing a public market for the Company's common stock, the estimated fair value of the Company's common stock was determined by the Company's board of directors as of the date of each option grant, with input from management, considering the Company's most recently available third-party valuations of common stock, recent sales of common stock to third parties, and the Company's board of directors' assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant.

JOBS Act Accounting Election

The Company qualifies as an emerging growth company (as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act)). The JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the

Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company's financial statements with another public company which is neither an early-stage company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Â Segments Â The Company currently operates in one reportable segment based on management's view of its business for purposes of evaluating performance and making operating decisions. Based upon this business model, the Company's Chief Executive Officer, whom the Company has determined to be its chief operating decision-maker, reviews financial information as one operating segment.

Â Recent Accounting Pronouncements Â In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures," which requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The guidance is effective for the Company's fiscal years beginning after December 15, 2024, with early adoption permitted. The Company does not expect the adoption of this standard to have any material impact on its financial statements.

Â The Company does not believe that any recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.

Â 12 Table of Contents

Â Correction of an Immaterial Error in the Prior Period Financial Statements Â During the fourth quarter of fiscal 2024 (March 31, 2024), the Company determined that the prior year financial statements had an error caused by an immaterial classification error of certain research and development expense in accordance with ASC 730 Research and Development Costs. As a result, certain prior year amounts have been revised for consistency with the current year presentation. The Company assessed the materiality of this change in presentation on prior period financial statements in accordance with SEC Staff Accounting Bulletin No. 99, "Materiality." (ASC Topic 250, Accounting Changes and Error Corrections). Based on this assessment, the Company concluded that these classification error corrections in its Statements of Operations are not material to any previously presented financial statements based upon overall considerations of both quantitative and qualitative factors. The corrections had no impact on the fiscal year 2023 Balance Sheet, Statements of Cash Flows, or Statement of Changes in Stockholders' Equity. Further, the immaterial corrections did not result in a change in operating losses, net loss, or basic or diluted earnings per share in the Income Statement.

Â A summary of immaterial corrections reflecting the prior period impact to the Company's Statement of Operations, for the quarter ended June 30, 2023 is shown below (in thousands):

	As Revised	June 30, 2023	As Reported
Research and development expense	\$523.8A	\$523.8A	\$523.8A
Net Loss	\$871.1A	\$871.1A	\$871.1A

Â Note 2 â Convertible Notes Payable Â On September 9, 2023, the Company's Board of Directors (the "Board") authorized an offering up to \$2.0 million in unsecured, non-interest bearing convertible promissory notes (the "Notes") and accompanying warrants (the "Bridge Financing Warrants") (collectively, the "Offering") that will mature on December 31, 2025. The Notes provided that, on the closing date of the IPO, the outstanding principal would be automatically converted into common stock at the conversion price of \$2.00. Each dollar in principal amount of Notes purchased were accompanied by a five-year Bridge Financing Warrant to purchase 0.25 shares of Common stock with an exercise price of \$1.00 per share. The Company records the Bridge Financing Warrants as a discount to the Notes. Â The Bridge Financing Warrants can be exercised from the date of Notes issuance through the five-year anniversary of the issuance of the Notes. The shares issuable pursuant to the Notes and Bridge Financing Warrants have a 180-day lock-up after the Company's IPO. Thereafter, the foregoing lock-up agreement will cease to apply to 25% of the purchased shares each month for a period of four months. The Note holders are not permitted to convert their Notes when the holders or any of their affiliates would beneficially own in excess of 4.99% of the Company's common stock after such conversion.

Â As of June 30, 2024, the Company received proceeds of \$2.0 million of Notes executed from the Bridge Offering, which would convert into 1.0 million shares of common stock. The Company's effective interest rate for the Notes is 15.3% due to the amortization of the discount stemming from the issuance of the Bridge Financing Warrants. On January 26, 2024, we consummated our initial public offering ("IPO"). In connection with the closing of the IPO, a portion of our convertible notes were converted into 335,000 shares of our common stock. Upon the closing of the IPO, certain notes were to be automatically converted according to their terms into our common stock to the extent and provided that certain holders of these notes are not permitted to convert such notes to the extent that the holders or any of its affiliates would beneficially own in excess of 4.99% of our common stock after such conversion. Due to this 4.99% limitation, principal representing \$1.3 million, or 665,000 shares, of these notes remains outstanding.

Â 13 Table of Contents

The table below summarizes the Company's outstanding convertible notes payable as of June 30, 2024 (in thousands).

	Principal Amount	Amortized Debt Discount	Net Carrying Amount	Zero-coupon convertible notes payable due on December 31, 2025
Convertible Notes Payable	\$1,043.4A	\$1,043.4A	\$1,043.4A	\$1,043.4A

Â Warrants Â The Company issued the Notes with detachable warrants for the purchase of shares of the Company's common stock. The Company utilized a Monte Carlo simulation model to determine the fair value of each Bridge Offering Warrant. The key inputs to the Monte Carlo simulation used to determine the fair value of each warrant include, the Company's stock price fair value which was determined through a back solve calculation such that the stock price results in the average total value of the Notes and the Bridge Offering Warrants being equal to the cash proceeds received, volatility based on a selection of publicly held peer companies of 101.88%, expected term of 5 years, risk free rate of 4.40%, discount rate of 20.00% and a discount for lack of marketability of 15.77%.

Â During the three months ended June 30, 2024, the Company recorded less than \$0.1 million in interest expense related to the amortization of the debt discount.

Â The following table presents a summary of activity for the warrants issued in connection with the Company's Notes:

	Weighted-Average Exercise Price	Remaining Life	Aggregate Warrants Per Share	Intrinsic Value*
Outstanding and exercisable, March 31, 2024	\$500,000A	\$1.00A	4.48A	\$1,010,000A
Granted	-	-	-	-
Expired	-	-	-	-
Forfeited/Cancelled	-	-	-	-
Outstanding, June 30, 2024	500,000A	1.00A	4.23A	-

*Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money warrants. No outstanding and exercisable warrants issued in connection with the Company's Notes were in-the-money as of June 30, 2024.

Â 14 Table of Contents

Â Note 3 â Equity Â On January 26, 2024, we consummated our IPO. In the IPO, we sold a total of 2,234,222 shares of common stock at a purchase price of \$5.00 per share for gross proceeds of \$11.2 million and net proceeds of \$9.8 million. In connection with the closing of the IPO, a portion of our convertible notes were converted into 335,000 shares of our common stock. Total shares of common stock outstanding at the closing of the IPO amounted to 18,687,061 shares, prior to the May 13, 2024 cancellation of 1,050 shares represented in the IPO for payment disputes. Upon the closing of the IPO, certain notes were to be automatically converted according to their terms into our common stock to the extent and provided that certain holders of these notes are not permitted to convert such notes to the extent that the holders or any of its affiliates would beneficially own in excess of 4.99% of our common stock after such conversion. Due to this 4.99% limitation, principal representing \$1.3 million, or 665,000 shares, of these notes remains outstanding.

Â On November 29, 2023, the Company's Board of Directors and applicable shareholders approved to amend and restate the Company's certificate of incorporation and increased the authorized shares to 500,000,000 shares of common stock, with a par value of \$.001 per share, and 10,000,000 shares of preferred stock, with a par value of \$.001 per share. The specific rights of the preferred stock shall be determined by the Board of Directors.

Â Restricted Stock Â On February 15, 2024, the Company issued 35,000 restricted shares of common stock to the Company's marketing consultant at the closing price of \$3.80 of the Company's common stock. The total value of these shares is \$133,000. These shares vest monthly over a 12-month period beginning on the issue date.

Â Quarter ended June 30, 2024

Â 2023

Recognized in general and administrative expense \$33,250A

Â sâ Total \$33,250A

Â For the quarter ended June 30, 2024, there was \$83,125 of unrecognized stock-based compensation expense related to unvested Restricted Stock, which is expected to be recognized over the period July 2024 through February 2025.

Â A summary of activity regarding Restricted Stock issued is as follows:

	Grant Date	Number of Shares	Fair Value Per Share	Unvested, March 31, 2024
Granted	32,083A	\$3.80A	\$3.80A	23,333A
Vested	32,083A	\$3.80A	\$3.80A	23,333A
Unvested, June 30, 2024	23,333A	\$3.80A	\$3.80A	23,333A

Â 15 Table of Contents

Â Common Stock Â On April 6, 2023, the Board of Directors approved a private placement offering of up to 2,000,000 common shares at a price of \$2.00 per share. During the three months ended June 30, 2023, the Company sold 1,420,000 shares for cash proceeds of \$2,840,000. The Company did not incur any costs that were direct and incremental to the private placement.

Â On September 9, 2023, the Board approved a Bridge Offering. See Note 3 Convertible Notes Payable for additional detail as these notes are convertible into common stock.

Â Stock Plan and Stock Options Â In June 2023, the Company adopted, and the Company's shareholders approved, the Autonomix Medical, Inc. 2023 Stock Plan (the "Plan"). The Plan is a stock-based compensation plan that provides for discretionary grants of stock options, stock awards and stock unit awards to key employees, non-employee directors, and consultants, subject to certain individual threshold limitations. The Plan provides for up to 4,000,000 shares to be issued. Shares that are surrendered because of forfeiture, expiration, termination, or cancellation are available for re-issuance.

Â In August 2023, the Plan was amended to allow for an automatic increase of the available shares for issuance, whereby on the 1st of each fiscal year, beginning on April 1, 2024 and ending on (and including) April 1, 2033 in an amount equal to five percent (5%) of the total number of shares of Common Stock outstanding on the March 31st immediately preceding the applicable date. However, the Board may act prior to the automatic increase of a given year to provide that there will be no increase for such year, or that the increase for such year will be a lesser number of shares of Common Stock.

On April 1, 2024, the Plan was increased by 942,305 shares.

Â The following table summarizes the stock option activity for the three months ended June 30, 2024:

	Weighted-Average Exercise Price	Remaining Life	Aggregate Warrants Per Share	Options Per Share	Intrinsic Value*
Outstanding and exercisable, March 31, 2024	2,003,600A	\$2.33A	9.35A	\$1,680,672A	Granted
Granted	3,235,979A	\$1.38A	\$1.38A	-	Expired
Expired	-	-	-	-	Outstanding, June 30, 2024
Forfeited/Cancelled	-	-	-	-	3,429,579A
Outstanding, June 30, 2024	1.82A	\$5.75A	\$5.75A	-	Exercisable
Exercisable, June 30, 2024	321,317A	\$2.00A	\$8.69A	-	*Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money stock. No outstanding or exercisable options were in-the-money as of June 30, 2024.

Â During the three months ended June 30, 2024, the Company granted certain individuals options to purchase 2,325,979 shares of common stock with an average exercise price of \$1.38 per share and a contractual term that vests annually over four years on the anniversary date. The options had an aggregate grant date fair value of \$2.6 million that was calculated using the Black-Scholes option pricing model. Variables used in the Black-Scholes option pricing model included the following: (1) fair value

and financial reporting services and pays certain expenses on behalf of the Company. During the three months ended June 30, 2024 and 2023, the Company incurred fees of \$0Â and less than \$0.1 million, respectively, for these services, excluding officer compensation. As of June 30, 2024 and March 31, 2024, the Company owed the consulting firm \$0 and less than \$0.1 million, respectively, for services and expenses. Â As of June 30, 2024, members of the Companyâ€™s management/Board and an immediate family member of the Companyâ€™s management (related party), collectively purchased \$0.5 million (\$0.4 million and \$0.1 million, respectively) of the Bridge Offering. Â 18 Table of Contents Â On December 21, 2021, the Company entered into a perpetual, worldwide, exclusive license agreement (the â€œLicenseâ€ or â€œLicense Agreementâ€) with a company controlled by a significant stockholder of the Company (the â€œLicenseeâ€). The License allows the Licensee to use certain intellectual property and technology related to the diagnosis and treatment of cardiovascular conditions held by the Company. Upon 90 days following the completion of an initial public offering or special purpose acquisition company transaction, the Licensee may enter into sublicenses of the licensed intellectual property and technology. Â On July 7, 2023, the Company and the Licensee entered into an Exclusive License Termination Agreement (the â€œTermination Agreementâ€) in exchange for the issuance, upon the closing of the Companyâ€™s initial public offering within one year of the agreementâ€™s execution, of a warrant to purchase shares of the Company for a variable number of shares. The variable number of shares issued was based upon a fixed value of \$8.0 million divided by the price per share in the offering. The warrants are exercisable at a price of \$0.001 per share and may be exercised any time after the issuance date, subject to a beneficial ownership limitation, and expires five years from the original issuance. The warrants provide voting rights, dividend rights, and other rights of a shareholder prior to exercise. The shares underlying the warrant will be subject to a lockup agreement for a period of six months after the closing of the offering with respect to 12.5% of the shares issued and twelve months after the closing of the offering for the remainder of the shares. Â On January 29, 2024, we issued a warrant to purchase 1,600,000 shares (the â€œWarrantâ€) pursuant to the Termination Agreement with Impulse Medical, Inc. ("Impulse"). The warrants are exercisable at a price of \$0.001 per share and may be exercised any time after the issuance date, subject to a beneficial ownership limitation, and expires five years from the original issuance. The warrants provide voting rights, dividend rights, and other rights of a shareholder prior to exercise. The shares underlying the Warrant are subject to a lockup agreement for a period of six months after the closing of the IPO with respect to 12.5% of the shares issued and twelve months after the closing of the IPO for the remainder of the shares. In connection with the Termination Agreement, the Company agreed to register the resale of the shares of common stock underlying the Warrant upon a notice of 20 business days by the Warrant holder. Â A Note 6 â€” Subsequent Events Â On July 10, 2024, we entered into a license agreement (the â€œAgreementâ€) with RF Innovations, Inc. (â€œRFIâ€), a privately held medical technology company, to license products utilizing RFIâ€™s intellectual property related to its Apex 6 Radiofrequency Generator (the â€œLicensed Productsâ€). The Apex 6 Generator is a United States Food and Drug Administration (â€œFDAâ€) cleared ablation technology designed to lesion neural tissue for pain management in the peripheral nervous system. Pursuant to the Agreement, RFI granted us a perpetual non-exclusive worldwide royalty free fully paid license related to the Licensed Products, provided that the license did not include the right to sell certain products to customers for the treatment of spine pain. In connection with the Agreement, we issued RFI 250,000 unregistered shares of our common stock as consideration for the license. The Agreement provides RFI the right to terminate the license if we breach any representation, warranty or covenant contained in the Agreement, subject to any relevant cure periods, or if we are subject to a bankruptcy or insolvency event. Â In July 2024, 3,594,000 warrants were exercised on a cashless basis resulting in a net share amount of 3,544,852 at an exercise price of \$0.01. Â 19 Table of Contents Â A Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Â References in this Form 10-Q to â€œwe,â€ â€œus,â€ â€œits,â€ â€œourâ€ or the â€œCompanyâ€ are to Autonomix Medical, Inc. (â€œAutonomixâ€), as appropriate to the context. Â You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the financial statements and the related notes appearing elsewhere in this Form 10-Q. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. See the section titled â€œRisk Factorsâ€ as found in the Annual Report in our Form 10-K filed with the SEC on May 31, 2024Â which is available on the SECâ€™s EDGAR website at www.sec.gov, for a discussion of the uncertainties, risks and assumptions associated with these statements. Actual results and the timing of events could differ materially from those discussed in our forward-looking statements as a result of many factors, including those set forth under â€œRisk Factorsâ€ and elsewhere in this Form 10-Q. Â CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Â We make forward-looking statements under the â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ and in other sections of this Form 10-Q. In some cases, you can identify these statements by forward-looking words such as â€œmay,â€ â€œmight,â€ â€œshould,â€ â€œwould,â€ â€œcould,â€ â€œexpect,â€ â€œplan,â€ â€œanticipate,â€ â€œintend,â€ â€œbelieve,â€ â€œestimate,â€ â€œpredict,â€ â€œpotentialâ€ or â€œcontinue,â€ and the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. In particular, you should consider the numerous risks and uncertainties described under â€œRisk Factorsâ€ as discussed in the Annual Report in our Form 10-K filed with the SEC on May 31, 2024 and in other filings made by us from time to time with the SEC. Â While we believe we have identified material risks, these risks and uncertainties are not exhaustive. Other sections of this Form 10-Q may describe additional factors that could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Â Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We are under no duty to update any of these forward-looking statements after the date of this Form 10-Q to conform our prior statements to actual results or revised expectations, and we do not intend to do so. Â Forward-looking statements include, but are not limited to, statements about: Â A Â€ the success of our future clinical trials; Â A Â€ competition from existing products or new products that may emerge; Â A Â€ potential product liability claims; Â A Â€ our dependency on third-party manufacturers to supply or manufacture our future products; Â A Â€ our ability to obtain all parts required to manufacture our devices; Â A 20 Table of Contents Â A Â€ our ability to establish or maintain collaborations, licensing or other arrangements; Â A Â€ our ability and third partiesâ€™ abilities to protect intellectual property rights; Â A Â€ our ability to raise additional capital to adequately support future growth; Â A Â€ our ability to attract and retain key personnel to manage our business effectively; Â A Â€ risks associated with our identification of material weaknesses in our control over financial reporting; Â A Â€ natural disasters affecting us, our primary manufacturer or our suppliers; Â A Â€ our ability to establish relationships with health care professionals and organizations; Â A Â€ general economic uncertainty that adversely affects spending on medical procedures; Â A Â€ volatility in the market price of our stock; and Â A Â€ potential dilution to current stockholders from the issuance of equity awards and from future capital raising activities. Â We caution you not to place undue reliance on the forward-looking statements, which speak only as of the date of this Form 10-Q in the case of forward-looking statements contained in this Form 10-Q. Â Overview Â We are a development stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Our first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies. We calculate sensitivity in units of minimum signal detection voltage in micro volts (uV) time area of the electrode (square millimeters). It is a combined measure that is related to the signal resolving power and spatial resolution of the system. For the BSC Orion, the nearest device on the market, the metrics are 10uV for signal detection levels, and roughly 0.4mm by 0.5mm for the electrode dimensions. For the Autonomix device, the metrics are <1uV for signal detection levels and roughly 0.02mm by 0.03mm for the electrode dimensions. The differences in these metrics result in a calculation of 3,000 times greater sensitivity for the Autonomix device. We believe, if we can recreate these results in clinical trials, this will enable a method of transvascular targeting, treating, and confirming treatment of diseases involving the nervous system throughout the body that is not currently available and may be capable of filling a wide range of unmet medical needs. Â We are initially developing our technology for patients with pancreatic cancer, a condition that can cause debilitating pain and needs a more effective solution. However, we believe our technology constitutes a platform with the potential to address dozens of indications in a range of areas including chronic pain management from all causes, hypertension, cardiovascular disease and a wide range of other nerve-related disorders. Â Our development efforts can be divided into to two sub parts: sensing and treatment, where sensing is focused on identifying neuronal activity that may be associated with a disorder with enough precision to enable targeted treatment. While the treatment may vary depending on the disorder, in our initial indications this will involve energy-based ablation (deliberate tissue damage, also referred to as denervation) intended to stop unwanted neuronal activity. Â Our sensing catheter has already been developed sufficiently to demonstrate in animal models successful identification of a signal from a specific nerve before ablation and confirmation of termination of the signal from the treated nerve after ablation. We are now in the process of improving the assembly of this catheter to meet the standards required for human use. In parallel with this effort, we are preparing for a first-in-human demonstration of transvascular ablation (without the use of our sensing technology) to relieve pain associated with pancreatic cancer. Once these two efforts are completed, we plan to bring sensing and treatment together in a pivotal clinical trial to enable the commercial launch of our technology. As stated above, we are a development stage company and there is no guarantee that the results of any trials will produce positive results or that the results will support our claims. Â 21 Table of Contents Â Recent Developments Â On July 10, 2024, we entered into a license agreement (the â€œAgreementâ€) with RF Innovations, Inc. (â€œRFIâ€), a privately held medical technology company, to license products utilizing RFIâ€™s intellectual property related to its Apex 6 Radiofrequency Generator (the â€œLicensed Productsâ€). The Apex 6 Generator is a United States Food and Drug Administration (â€œFDAâ€) cleared ablation technology designed to lesion neural tissue for pain management in the peripheral nervous system. Pursuant to the Agreement, RFI granted us a perpetual non-exclusive worldwide royalty free fully paid license related to the Licensed Products, provided that the license did not include the right to sell certain products to customers for the treatment of spine pain. In connection with the Agreement, we issued RFI 250,000 unregistered shares of our common stock as consideration for the license. The Agreement provides RFI the right to terminate the license if we breach any representation, warranty or covenant contained in the Agreement, subject to any relevant cure periods, or if we are subject to a bankruptcy or insolvency event. Â Results of Operations for the Three Months Ended June 30, 2024 Compared to the Three Months Ended June 30, 2023 Â Below is a summary of the results of operations (in thousands): Â A Â€ Three Months Ended June 30, Â A Â€ Â A Â€ Â A Â€ Â A Â€ Â A Â€ Change Â A Â€ Change Â A Â€ 2024 Â A Â€ 2023 Â A Â€ (\$) Â A Â€ (%) Â Operating expenses: Â A Â€ Â A Â€ Â A Â€ Â A Â€ Â A Â€ Â A Â€ Â A Â€ General and administrative Â \$ 1,799 Â A Â€ \$ 503 Â A Â€ \$ 1,296 Â A Â€ 258 % Research and development Â A Â€ 954 Â A Â€ 368 Â A Â€ 586 Â A Â€ 159 % Total operating expenses Â \$ 2,753 Â A Â€ \$ 871 Â A Â€ \$ 1,882 Â A Â€ 216 % Â A General and Administrative Expense Â General and administrative expense was \$1.8Â million for the three months ended June 30, 2024 compared to \$0.5Â million for the same period in 2023. This \$1.3Â million increase was driven primarily by increases in officer and employee compensation and benefits of \$0.6 million, as we expanded our management team, stock-based compensation of \$0.3 million, legal and professional fees of \$0.2 million, insurance expense of \$0.1 million, franchise tax of \$0.1 million and other expenses of \$0.1 million, offset by a decrease in advertising expense of \$0.1 million. Â Research and Development Expense Â Research and development expense was \$1.0 million for the three months ended June 30, 2024 compared to \$0.4 million for the same period in 2023. The increase in research and development expenses during the current year was mainly attributed to clinical trial planning and development cost. We expect to incur increased research and development costs in the future as we continue our clinical trial. Â Interest expense Â For the three months ended June 30, 2024, we had interest expense of less than \$0.1 million, related to the amortization of debt discount. Interest expense was \$0 during the three months ended June 30, 2023 as there was no comparable instrument or expense in the prior period. Â Interest income Â For the three months ended June 30, 2024, we had interest income of \$0.1 million. Interest income for the three months ended June 30, 2023 was less than \$0.1 million due to relatively lower cash balances. Â 22 Table of Contents Â Liquidity and Capital Resources Â On June 30, 2024, we had cash of \$6.8 million, and working capital of \$6.3 million. We have historically funded our operations from proceeds from debt and equity sales. We estimate our current cash resources are sufficient to fund our operations into but not beyond the second calendar quarter of 2025. Â Our plan of operations is primarily focused on developing our initial product, which is currently in the proof-of-concept stage at this time. We are initially focusing on the treatment of pain associated with pancreatic cancer and we have designed our commercialization efforts around this as our first proposed indication for use. Â We will need to raise additional capital to meet our obligations and execute our business plan. We estimate that we will require additional financing of approximately \$40 million to fund our operations through our clinical phase. The timing and costs of clinical trials are difficult to predict and trial plans may change in response to evolving circumstances and as such the foregoing estimates may prove to be inaccurate. If we are unable to raise sufficient funds, we will be required to develop and implement an alternative plan to further extend payables, reduce overhead or scale back our business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. The Company recognizes it will need to raise additional capital to continue to execute its business plan, including obtaining regulatory clearance for its products currently under development and commercializing and generating revenues from products under development. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company. A failure to raise sufficient capital, generate sufficient product revenues, control expenditures and regulatory matters, among other factors, will adversely impact the Companyâ€™s ability to meet its financial obligations as they become due and payable and to achieve its intended business objectives. If the Company is unable to raise sufficient additional funds, it will have to scale back its operations. Â Summary of Cash Flows Â Cash used in operating activities Â Net cash used in operating activities was \$1.9 million during the three months ended June 30, 2024, consisting of a net loss of \$2.7 million and a decrease in operating assets and liabilities of \$0.5Â million. The change in operating assets and liabilities included sources of cash from a decrease in other current assets of \$0.5 million and an increase in accrued expenses of \$0.2 million offset by a use of cash decrease for accounts payable of \$0.2 million. The decrease in other current assets was driven primarily by the receipt of funds from our marketing partner that were a holdback from our IPO and the amortization of prepaid insurance costs. The increase in accrued expenses and the decrease in accounts payable are offsetting and are driven primarily by the timing of receipt of vendor invoices. Non-cash items consisted of stock-based compensation of \$0.4 million. Â Cash used in investing activities Â Net cash used in investing activities was \$5 thousand for the three months ended June 30, 2024 related to the purchase of computer hardware and software. Â Cash provided by financing activities Â Net cash provided by financing activities was \$0Â for the three months ended June 30, 2024. Â Net cash provided by financing activities was \$2.7 million for the three months ended June 30, 2023 consisting of \$2.8 million from the sale of common stock.Â We also paid \$0.1 million in offering costs related to our IPO. Â Contractual Obligations and Commitments Â None. Â Employment Arrangements Â We have agreements with key employees to provide certain benefits, including salary and other wage-related benefits, in the event of termination. In addition, the Company has adopted a severance policy for certain key members of executive management to provide certain benefits, including salary and other wage-related benefits, in the event of termination. In total, these benefits would amount to a range of \$1.1 million to \$1.6Â million using the rate of compensation in effect at June 30, 2024. Â 23 Table of Contents Â Off-balance Sheet Arrangements Â As of June 30, 2024 and March 31, 2024, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. Â Critical Accounting Policies and Significant Judgments and Estimates Â The financial statements in this quarterly report have been prepared in accordance with generally accepted accounting principles in the United States of America (â€œGAAPâ€). The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements, including the notes thereto. We consider critical accounting policies to be those that require more significant judgments and estimates in the preparation of our financial statements, including the following: research and development expenses, accrued liabilities, income tax valuations, warrants, and stock-based compensation. Management relies on historical experience and other assumptions believed to be reasonable in making its judgments and estimates. Actual results could differ materially from those estimates. Â Management believes its application of accounting policies, and the estimates inherently required therein, are reasonable. These accounting policies and estimates are periodically reevaluated, and adjustments are made when facts and circumstances dictate a change. Â Our accounting policies are more fully described

under the heading “Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies” in Note 1 of our Annual Report on Form 10-K filed with the SEC on May 31, 2024. Á Item 3. Quantitative and Qualitative Disclosures About Market Risk Á We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item. Á Item 4. Controls and Procedures Á Evaluation of Disclosure Controls and Procedures Á Changes in Internal Control over Financial Reporting Á We maintain a set of disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, designed to ensure that material information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that material information is accumulated and communicated to our management, including our Chief Executive Officer (the “CEO”), who serves as our principal executive officer, and Chief Financial Officer (the “CFO”), who serves as our principal accounting officer, as appropriate, to allow timely decisions regarding required disclosures. Á Under the supervision, and with the participation of our management, including our CEO and CFO, we conducted an evaluation of the effectiveness, as of June 30, 2024, of our disclosure controls and procedures. Based upon such evaluation and due to both the limited staffing of the Company at its early stage of development and the existence of the material weaknesses in our internal control over financial reporting described below, our CEO and CFO have concluded that, as of June 30, 2024, our disclosure controls and procedures were not effective. Á A material weakness is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected. As previously disclosed in the Annual Report in our Form 10-K filed with the SEC on May 31, 2024, our management concluded that our internal control over financial reporting was, and continues to be, ineffective as of June 30, 2024 due to material weaknesses in our internal controls arising from a lack of segregation of duties; general technology controls; and financial statement reporting. It should be noted that any system of controls, however well designed and operated, can provide only reasonable and not absolute assurance that the objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of certain events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote. Á 24 Table of Contents Á Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. Management evaluated the impact of our failure to maintain effective segregation of duties on our assessment of our internal control over financial reporting and has concluded that the control deficiency represents a material weakness. As previously disclosed, in our Form 10-K for the fiscal year ending March 31, 2024, we hired new executive officers and management with significant financial and accounting experience in both private and public companies. During the three months ended June 30, 2024, an additional experienced staff was hired in the accounting and finance department. We have added the use of additional consulting firms to assist with significant and complex accounting transactions and to assist with our segregation of duties and create a more structured financial statement reporting environment. Experienced personnel will be hired in the accounting and finance department and appropriate consultants will be upgraded as soon as it becomes economically feasible and sustainable. In addition, management has added additional mitigating controls with regards to cash disbursements; changes were made in our authorization processes to improve segregation of duties; and we performed additional analysis and other post-closing procedures to ensure our financial statements were prepared in accordance with generally accepted accounting principles. Accordingly, we believe that the financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented. Á Changes in Internal Control over Financial Reporting Á We have not experienced any material impact to our internal controls over financial reporting despite the fact that our employees are working remotely. We are continually monitoring and assessing the situation on our internal controls to minimize the impact on their design and operating effectiveness. Á Other than as described above, there has been no change in our internal control over financial reporting during our most recent calendar quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Á 25 Table of Contents Á PART II - OTHER INFORMATION Á Item 1. Legal Proceedings Á From time to time, in the ordinary course of our business, we may be involved in legal proceedings, the outcomes of which may not be determinable. The results of litigation are inherently unpredictable. Any claims against us, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. We are not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable. We have insurance policies covering potential losses where such coverage is cost effective. Á Item 1A. Risk Factors Á In addition to the other information set forth in this report, you should carefully consider the factors discussed in the section entitled “Risk Factors” as found in the Annual Report in our Form 10-K filed with the SEC on May 31, 2024. Á The risks described in our Form 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. There have been no material changes to our risk factors from those set forth in our Form 10-K filed with the SEC on May 31, 2024. Á Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Á On June 17, 2024, we entered into an employment agreement with Brad Hauser pursuant to which Mr. Hauser agreed to serve as our chief executive officer and president for an initial three-year period, which may be extended on a year-to-year basis. Pursuant to the agreement, Mr. Hauser was granted a ten-year option (the “Inducement Options”) to purchase 900,000 shares of common stock at an exercise price equal to the closing price of our common stock on the date of the employment agreement. The option vests in four equal annual installments (or 225,000 shares each installment) on each of the succeeding four anniversary dates of the execution of the employment agreement, provided Mr. Hauser is employed by us on each vesting date. In the event of a change of control or the termination of the agreement by us without cause or by Mr. Hauser for good reason, all of the unvested options shall immediately vest. The Inducement Options were granted outside of our 2023 Stock Plan as an inducement material to Mr. Hauser’s entering into employment with us in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). Á All of the securities were issued in reliance on the exemption provided by Section 4(a)(2) of the Securities Act for the offer and sale of securities not involving a public offering, and/or Regulation D promulgated under the Securities Act. Á Item 3. Defaults Upon Senior Securities Á None. Á Item 4. Mine Safety Disclosures Á Not applicable. Á Item 5. Other Information Á During the period covered by this Quarterly Report, none of the Company’s directors or executive officers has adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended). Á 26 Table of Contents Á Item 6. Exhibits Á INDEX TO EXHIBITS Á Exhibit Number Á Description 3.1 Á Amended and Restated Certificate of Incorporation of Autonomix Medical, Inc. Á (incorporated by reference from exhibit 2.1 of the Form 1-A POS, file number 024-12296, filed January 19, 2024) 3.2 Á Amended and Restated Bylaws of Autonomix Medical, Inc. Á (incorporated by reference from exhibit 2.2 of the Form 1-A POS, file number 024-12296, filed January 19, 2024) 10.1 Á Employment Agreement between Brad Hauser and Autonomix Medical, Inc. dated June 17, 2024 (incorporated by reference from exhibit 10.1 of the Form 8-K, filed June 17, 2024) 10.2 Á Employment Agreement between Lori Bisson and Autonomix Medical, Inc. dated June 17, 2024 (incorporated by reference from exhibit 10.2 of the Form 8-K, filed June 17, 2024) 31.1* Á Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934. 31.2* Á Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934. 32.1*(1) Á Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 32.2*(1) Á Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Á Á 101.INS* Á Inline XBRL Instance Document 101.SCH* Á Inline XBRL Taxonomy Extension Schema Document 101.CAL* Á Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF* Á Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB* Á Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE* Á Inline XBRL Taxonomy Extension Presentation Linkbase Document 104* Á Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) Á * Filed herewith. Á (1) The certifications on Exhibit 32 hereto are deemed not to be filed for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act. Á 27 Table of Contents Á SIGNATURES Á Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Á AUTONOMIX MEDICAL, INC. Á SIGNATURE Á TITLE Á DATE Á Á Á /s/ Brad Hauser Á Chief Executive Officer and President Á August 13, 2024 Brad Hauser Á (principal executive officer) Á Á Á Á /s/ Trent Smith Á Chief Financial Officer and Executive Vice-President Á August 13, 2024 Trent Smith Á (principal financial and accounting officer) Á Á 28 EX-31.1 2 ex 652079.htm EXHIBIT 31.1 ex 652079.htm Exhibit 31.1 Á CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Á I, Brad Hauser, certify that: Á 1. Á Á I have reviewed this Quarterly Report on Form 10-Q of Autonomix Medical, Inc.; Á 2. Á Á Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Á 3. Á Á Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Á 4. Á Á The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: Á (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Á Á Á (b) Intentionally omitted; Á Á Á (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Á Á Á (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s internal control over financial reporting; and Á 5. Á Á The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): Á (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and Á Á Á (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. Á Date: August 13, 2024 Á /s/ Brad Hauser Á Brad Hauser Á Chief Executive Officer and President Á (Principal Executive Officer) Á Á EX-31.2 3 ex 652080.htm EXHIBIT 31.2 ex 652080.htm Exhibit 31.2 Á CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Á I, Trent Smith, certify that: Á 1. Á Á I have reviewed this Quarterly Report on Form 10-Q of Autonomix Medical, Inc.; Á 2. Á Á Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Á 3. Á Á Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Á 4. Á Á The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: Á (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Á Á Á (b) Intentionally omitted; Á Á Á (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Á Á Á (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s internal control over financial reporting; and Á 5. Á Á The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): Á (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and Á Á Á (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. Á Date: August 13, 2024 Á /s/ Trent Smith Á Trent Smith Á Chief Financial Officer and Executive Vice-President Á (Principal Financial and Accounting Officer) Á Á EX-32.1 4 ex 652081.htm EXHIBIT 32.1 ex 652081.htm Exhibit 32.1 Á CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Á I, Brad Hauser, do hereby certify, pursuant to 18 USC Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge: Á 1. The Quarterly Report on Form 10-Q of Autonomix Medical, Inc. for the quarter ended June 30, 2024, as filed with the Securities and Exchange Commission (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Á 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Á Date: August 13, 2024 Á /s/ Brad Hauser Á Brad Hauser Á Chief Executive Officer and President Á (Principal Executive Officer) Á Á EX-32.2 5 ex 652082.htm EXHIBIT 32.2 ex 652082.htm Exhibit 32.2 Á CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Á I, Trent Smith, do hereby certify, pursuant to 18 USC Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge: Á 1. The Quarterly Report on Form 10-Q of Autonomix Medical, Inc. for the quarter ended June 30, 2024, as filed with the Securities and Exchange Commission (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Á 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Á Date: August 13, 2024 Á /s/ Trent Smith Á Trent Smith Á Chief Financial Officer and Executive Vice-President Á (Principal Financial and Accounting Officer) Á Á EX-101.SCH 6 amix-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Balance Sheets (Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Balance Sheets (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Convertible Notes Payable link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Equity link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 995458 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 995459 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 995460 - Disclosure - Note 2 - Convertible Notes Payable (Tables) link:calculationLink link:definitionLink link:presentationLink 995461 - Disclosure - Note 3 - Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 995462 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995463 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities (Details) link:calculationLink link:definitionLink

link:presentationLink 995464 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Prior Period Corrections (Details) link:calculationLink link:definitionLink link:presentationLink 995465 - Disclosure - Note 2 - Convertible Notes Payable (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995466 - Disclosure - Note 2 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) link:calculationLink link:definitionLink link:presentationLink 995467 - Disclosure - Note 2 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 995468 - Disclosure - Note 2 - Convertible Notes Payable - Schedule of Detachable Warrants (Details) link:calculationLink link:definitionLink link:presentationLink 995469 - Disclosure - Note 3 - Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995470 - Disclosure - Note 3 - Equity - General and Administrative Expense (Details) link:calculationLink link:definitionLink link:presentationLink 995471 - Disclosure - Note 3 - Equity - Restricted Stock Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995472 - Disclosure - Note 3 - Equity - Schedule of Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995473 - Disclosure - Note 3 - Equity - Schedule of Equity-Based Stock Warrants (Details) link:calculationLink link:definitionLink link:presentationLink 995474 - Disclosure - Note 4 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995475 - Disclosure - Note 5 - Related Party Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995476 - Disclosure - Note 6 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 amix-20240630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 amix-20240630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 amix-20240630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Fair Value of Financial Instruments, Policy [Policy Text Block] Note To Financial Statement Details Textual Significant Accounting Policies Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies Valuation Approach and Technique [Axis] Note 2 - Convertible Notes Payable Valuation Approach and Technique [Domain] Note 3 - Equity Segment Reporting, Policy [Policy Text Block] Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities (Details) Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Prior Period Corrections (Details) Note 2 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) Long term liabilities: Note 2 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) (Parentheticals) Note 2 - Convertible Notes Payable - Schedule of Detachable Warrants (Details) Note 3 - Equity - General and Administrative Expense (Details) Note 3 - Equity - Restricted Stock Activity (Details) Note 3 - Equity - Schedule of Stock Option Activity (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate us-gaap_ShareBasedCompensation Stock-based compensation Note 3 - Equity - Schedule of Equity-Based Stock Warrants (Details) us-gaap_DebtConversionConvertedInstrumentSharesIssued1 Debt Conversion, Converted Instrument, Shares Issued (in shares) us-gaap_LiabilitiesCurrent Total current liabilities Notes To Financial Statements Notes To Financial Statements [Abstract] Convertible Debt [Table Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1 Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year) Earnings Per Share, Policy [Policy Text Block] Outstanding, warrants, weighted average remaining contractual term (Year) us-gaap_RevenuesRevenues Debt Conversion Description [Axis] amix_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount Rate The interest rate assumption that is used in valuing an option on its own shares. Underlying Asset Class [Domain] Debt Conversion, Name [Domain] Outstanding, warrants, aggregate intrinsic value Scenario, Contract Termination [Member] Information pertaining to the termination of the employment contract. Amortized debt discount Exercisable, warrants, aggregate intrinsic value Black-Scholes Model [Member] Black-Scholes-Merton used to estimate fair value of award under share-based payment arrangement. Income Tax, Policy [Policy Text Block] us-gaap_LiabilityForUncertainTaxPositionsCurrent Liability for Uncertainty in Income Taxes, Current Share-Based Payment Arrangement, Option, Activity [Table Text Block] Underlying Asset Class [Axis] Granted, unvested restricted stock units, weighted average grant date fair value (in dollars per share) Vested restricted stock units, weighted average grant date fair value (in dollars per share) Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Balance, unvested restricted stock units, weighted average grant date fair value (in dollars per share) Balance, unvested restricted stock units, weighted average grant date fair value (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Balance, unvested restricted stock units, shares (in shares) Balance, unvested restricted stock units, shares (in shares) Research and Development Expense, Policy [Policy Text Block] Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block] Granted, unvested restricted stock units, shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Vested restricted stock units, shares (in shares) Depreciation and amortization expense us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share (in dollars per share) Exercisable, options, weighted average exercise price (in dollars per share) us-gaap_AssetsCurrent Total current assets Exercisable, options, Weighted average remaining contractual term (Year) Long term assets: Exercisable, June 30, 2024* Share-Based Payment Arrangement [Policy Text Block] Equity [Text Block] us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value (in dollars per share) Exercisable, options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number (in shares) Outstanding, options, Weighted average remaining contractual term (Year) Outstanding and exercisable, March 31, 2024 Advertising Cost [Policy Text Block] Common stock, \$0.001 par value, 500,000,000 shares authorized as of June 30, 2024 and March 31, 2024, respectively, 19,242,081 and 18,846,094 shares issued and outstanding as of June 30, 2024 and March 31, 2024, respectively Common Stock, Value, Issued Adjustments to reconcile net loss to net cash used in operating activities: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, options, weighted average exercise price (in dollars per share) Outstanding, options, weighted average exercise price (in dollars per share) Common stock, authorized (in shares) Common Stock, Shares Authorized (in shares) Forfeited/Cancelled, options, weighted average exercise price (in dollars per share) Common stock, issued (in shares) Common Stock, Shares, Issued (in shares) Expired, options, weighted average exercise price (in dollars per share) Stockholders' Equity, Policy [Policy Text Block] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number (in shares) Outstanding, warrants (in shares) Outstanding, warrants (in shares) Granted, options, weighted average exercise price (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) Exercised, options, weighted average exercise price (in dollars per share) Revision of Prior Period [Axis] Accrued expenses Revision of Prior Period [Domain] Previously Reported [Member] Revision of Prior Period, Adjustment [Member] Statistical Measurement [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised Exercised, warrants (in shares) Maximum [Member] Non-cash financing activities: Minimum [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures Forfeited/Cancelled, warrants (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations Expired, warrants (in shares) Accounts payable Ownership [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease) (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares) Outstanding, options (in shares) Outstanding, options (in shares) Other current assets Statistical Measurement [Axis] Granted, warrants (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Expired, options (in shares) Debt, Policy [Policy Text Block] Ownership [Axis] Preferred stock, \$0.001 par value, 10,000,000 shares authorized as of June 30, 2024 and March 31, 2024, respectively, no shares issued and outstanding as of June 30, 2024 and March 31, 2024, respectively us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Preferred stock, issued (in shares) us-gaap_PolicyTextBlockAbstract Accounting Policies us-gaap_LossContingencyPendingClaimsNumber Loss Contingency, Pending Claims, Number Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized (in shares) Cashless exercise of warrants Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share (in dollars per share) Refund of common stock from IPO (in shares) Stock Refunded During Period, Shares, IPO Common Stock (in shares) Represents the common shares refunded during the period. us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of property and equipment us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Share-Based Payment Arrangement, Tranche Three [Member] Current liabilities: Vesting [Axis] Vesting [Domain] Share-Based Payment Arrangement, Tranche One [Member] Share-Based Payment Arrangement, Tranche Two [Member] us-gaap_Assets Total Assets us-gaap_LongTermDebtFairValue Long-Term Debt, Fair Value us-gaap_PropertyPlantAndEquipmentUsefulLife Property, Plant and Equipment, Useful Life (Year) Plan Name [Axis] Plan Name [Domain] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Employment Contracts [Member] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost not yet recognized, Amount Cash Flows from Operating Activities: amix_AnnualBaseSalary Annual Base Salary Represents the annual base salary. Statement [Line Items] RF Innovations, Inc. [Member] Represents information pertaining to RF Innovations, Inc. us-gaap_NumberOfOperatingSegments Number of Operating Segments us-gaap_NumberOfReportableSegments Number of Reportable Segments Executive Vice Chair and Strategic Advisor to the Chief Executive Officer [Member] Represents information pertaining to the executive vice chair and strategic advisor to the CEO. Additional paid-in capital Inducement Options [Member] Represents information pertaining to inducement options. Stockholders' equity: Property, Plant and Equipment, Policy [Policy Text Block] Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] us-gaap_NonoperatingIncomeExpense Total other income Award Type [Domain] Chief Financial Officer [Member] Chief Executive Officer [Member] Current assets: Net Loss Net Income (Loss) Attributable to Parent Net loss Award Type [Axis] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents, at beginning of period Cash and cash equivalents, at end of period IPO [Member] Private Placement [Member] Interest income us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net change in cash and cash equivalents Restricted Stock [Member] us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities us-gaap_Liabilities Total Liabilities Commitments and contingencies (Note 5) Sale of Stock [Axis] Sale of Stock [Domain] Convertible Debt Securities [Member] us-gaap_OperatingIncomeLoss Loss from operations us-gaap_NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Share-Based Payment Arrangement, Option [Member] Other (expense) income: Warrant [Member] us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Litigation Status [Axis] Litigation Status [Domain] Pending Litigation [Member] Commitments and Contingencies Disclosure [Text Block] Management [Member] Fixed assets, net us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent Accounts Payable and Accrued Liabilities us-gaap_PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs Payment of offering costs Long-Term Debt, Type [Axis] Long-Term Debt, Type [Domain] Cash Flows from Investing Activities: Scenario [Domain] Retained Earnings [Member] Convertible Debt [Member] Issuance of common stock us-gaap_ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock Title and Position [Domain] Title and Position [Axis] Scenario [Axis] us-gaap_RelatedPartyTransactionAmountsOfTransaction Related Party Transaction, Amounts of Transaction Additional Paid-in Capital [Member] Common Stock [Member] Related Party Transactions Disclosure [Text Block] Preferred Stock [Member] Income taxes Income Tax Expense (Benefit) us-gaap_IncreaseDecreaseInAccruedLiabilities Accrued expenses Equity Components [Axis] Equity Component [Domain] us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) us-gaap_ClassOfWarrantOrRightOutstanding Balance, outstanding (in shares) Balance, outstanding (in shares) us-gaap_ConvertibleNotesPayable Convertible Notes Payable us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Loss before income taxes us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) us-gaap_OperatingExpenses Total operating expenses us-gaap_IncreaseDecreaseInAccountsPayableTrade Accounts payable General and administrative expense Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value us-gaap_InterestExpenseNonoperating Interest expense us-gaap_DebtInstrumentConvertibleConversionPrice1 Debt Instrument, Convertible, Conversion Price (in dollars per share) us-gaap_AllocatedShareBasedCompensationExpense Share-Based Payment Arrangement, Expense us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments Debt Instrument, Convertible, Number of Equity Instruments Cash and Cash Equivalents, Policy [Policy Text Block] Document Quarterly Report Amendment Flag Entity Incorporation, State or Country Code General and Administrative Expense [Member] Accounting Policies [Abstract] Document Transition Report City Area Code Basis of Accounting, Policy [Policy Text Block] Maturity date Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Entity Interactive Data Current Related Party [Member] Reclassification, Comparability Adjustment [Policy Text Block] us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Security Exchange Name Common stock, outstanding (in shares) Common Stock, Shares, Outstanding (in shares) Preferred stock, outstanding (in shares) Title of 12(b) Security Current Fiscal Year End Date Changes in operating liabilities - (decrease)/increase: us-gaap_ProceedsFromConvertibleDebt Proceeds from Convertible Debt us-gaap_DebtInstrumentInterestRateEffectivePercentage Debt Instrument, Interest Rate, Effective Percentage Research and Development Expense [Member] Document Fiscal Period Focus Document Fiscal Year Focus Document Period End Date Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Entity File Number Entity Ex Transition Period Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Entity Emerging Growth Company Zero-coupon convertible notes payable due on December 31, 2025 us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Document Type Entity Small Business Entity Shell Company Document Information [Line Items] Document Information [Table] us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners Subsidiary, Ownership Percentage, Noncontrolling Owner Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status Debt Instrument, Name [Domain] Issuance of common stock - warrants exercised (in shares) Stock Issued During Period, Shares, Warrants Exercised (in shares) Number of warrants exercised during the current period. Issuance of common stock - warrants exercised Value of stock issued as a result of the exercise of warrants. Autonomix Medical, Inc [Member]

[illegible]

true Â Document Period End Date Jun. 30, 2024 Â Document Transition Report false Â Entity File Number 001-41940 Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 47-1607810 Â Entity Address, Address Line One 21 Waterway Avenue, Suite 300 Â Entity Address, City or Town The Woodlands Â Entity Address, State or Province TX Â Entity Address, Postal Zip Code 77380 Â City Area Code 713 Â Local Phone Number 588-6150 Â Title of 12(b) Security Common Stock, \$0.001 par value Â Trading Symbol AMIX Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company true Â Entity Ex Transition Period false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 23,036,933 X - Definition Boolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_Data Type: xbrli:normlizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_Data Type: xbrli:MonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_Data Type: xbrli:YearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_Data Type: xbrli:normlizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_Data Type: xbrli:normlizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_Data Type: xbrli:normlizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 7A -Section B -Subsection 2 + Details Name: dei_EntityExTransitionPeriod Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_Data Type: xbrli:normlizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_Data Type: xbrli:normlizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 14 R2.htm IDEA: XBRL DOCUMENT v.3.24.2.u1 Condensed Balance Sheets (Unaudited) - USD (\$) \$ in Thousands Jun. 30, 2024 Mar. 31, 2024 Current assets: Â Â Cash and cash equivalents \$ 6,751 \$ 8,608 Other current assets 325 783 Total current assets 7,076 9,391 Long term assets: Â Â Fixed assets, net 19 16 Total long term assets 19 16 Total Assets 7,095 9,407 Current liabilities: Â Â Accounts payable 287 492 Accrued expenses 476 285 Total current liabilities 763 777 Long term liabilities: Â Â Long term debt - convertible notes, net of unamortized debt discount 1,043 1,002 Total long term liabilities 1,043 1,002 Total Liabilities 1,806 1,779 Commitments and contingencies (Note 5) Stockholders' equity: Â Â Preferred stock, \$0.001 par value, 10,000,000 shares authorized as of June 30, 2024 and March 31, 2024, respectively, no shares issued and outstanding as of June 30, 2024 and March 31, 2024, respectively 0 0 Common stock, \$0.001 par value, 500,000,000 shares authorized as of June 30, 2024 and March 31, 2024, respectively 19,242,081 and 18,846,094 shares issued and outstanding as of June 30, 2024 and March 31, 2024, respectively 19 19 Additional paid-in capital 46,938 46,578 Accumulated deficit (41,668) (38,969) Total Stockholders' Equity 5,289 7,628 Total Liabilities and Stockholders' Equity \$ 7,095 \$ 9,407 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19) (a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a) (1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479150/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI

10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14): [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15): <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(14\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/21474780097/470-10-S99-1Reference 18](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/21474780097/470-10-S99-1Reference 18): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 19](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 19): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 20](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 20): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 21](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 21): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 22](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 22): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 23](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 23): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 24](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 24): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 25](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 25): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 26](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 26): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 27](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 27): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29):

ASB - URL

diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. Generally, the Company's outstanding warrants are non-participating securities as they are not entitled to non-forfeitable rights to dividends or dividend equivalents during the vesting term and have no obligation to fund losses. However, the warrants described in Note 5A are participating securities as they receive a right to dividends, but they are not obligated to fund losses. In periods of loss, since no income is allocated to these securities, the Company's use of the treasury stock method derives the same result. The dilutive effect of convertible securities is calculated using the if-converted method. Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted calculation for the entire period being presented. For the three months ended June 30, 2024 and 2023, dilutive securities that were not included in the calculations of the loss per common share because they would be anti-dilutive included the following: As of June 30, 2024, 2023, 2022, 2021, 2020, 2019, 2018, 2017, 2016, 2015, 2014, 2013, 2012, 2011, 2010, 2009, 2008, 2007, 2006, 2005, 2004, 2003, 2002, 2001, 2000, 1999, 1998, 1997, 1996, 1995, 1994, 1993, 1992, 1991, 1990, 1989, 1988, 1987, 1986, 1985, 1984, 1983, 1982, 1981, 1980, 1979, 1978, 1977, 1976, 1975, 1974, 1973, 1972, 1971, 1970, 1969, 1968, 1967, 1966, 1965, 1964, 1963, 1962, 1961, 1960, 1959, 1958, 1957, 1956, 1955, 1954, 1953, 1952, 1951, 1950, 1949, 1948, 1947, 1946, 1945, 1944, 1943, 1942, 1941, 1940, 1939, 1938, 1937, 1936, 1935, 1934, 1933, 1932, 1931, 1930, 1929, 1928, 1927, 1926, 1925, 1924, 1923, 1922, 1921, 1920, 1919, 1918, 1917, 1916, 1915, 1914, 1913, 1912, 1911, 1910, 1909, 1908, 1907, 1906, 1905, 1904, 1903, 1902, 1901, 1900, 1899, 1898, 1897, 1896, 1895, 1894, 1893, 1892, 1891, 1890, 1889, 1888, 1887, 1886, 1885, 1884, 1883, 1882, 1881, 1880, 1879, 1878, 1877, 1876, 1875, 1874, 1873, 1872, 1871, 1870, 1869, 1868, 1867, 1866, 1865, 1864, 1863, 1862, 1861, 1860, 1859, 1858, 1857, 1856, 1855, 1854, 1853, 1852, 1851, 1850, 1849, 1848, 1847, 1846, 1845, 1844, 1843, 1842, 1841, 1840, 1839, 1838, 1837, 1836, 1835, 1834, 1833, 1832, 1831, 1830, 1829, 1828, 1827, 1826, 1825, 1824, 1823, 1822, 1821, 1820, 1819, 1818, 1817, 1816, 1815, 1814, 1813, 1812, 1811, 1810, 1809, 1808, 1807, 1806, 1805, 1804, 1803, 1802, 1801, 1800, 1799, 1798, 1797, 1796, 1795, 1794, 1793, 1792, 1791, 1790, 1789, 1788, 1787, 1786, 1785, 1784, 1783, 1782, 1781, 1780, 1779, 1778, 1777, 1776, 1775, 1774, 1773, 1772, 1771, 1770, 1769, 1768, 1767, 1766, 1765, 1764, 1763, 1762, 1761, 1760, 1759, 1758, 1757, 1756, 1755, 1754, 1753, 1752, 1751, 1750, 1749, 1748, 1747, 1746, 1745, 1744, 1743, 1742, 1741, 1740, 1739, 1738, 1737, 1736, 1735, 1734, 1733, 1732, 1731, 1730, 1729, 1728, 1727, 1726, 1725, 1724, 1723, 1722, 1721, 1720, 1719, 1718, 1717, 1716, 1715, 1714, 1713, 1712, 1711, 1710, 1709, 1708, 1707, 1706, 1705, 1704, 1703, 1702, 1701, 1700, 1699, 1698, 1697, 1696, 1695, 1694, 1693, 1692, 1691, 1690, 1689, 1688, 1687, 1686, 1685, 1684, 1683, 1682, 1681, 1680, 1679, 1678, 1677, 1676, 1675, 1674, 1673, 1672, 1671, 1670, 1669, 1668, 1667, 1666, 1665, 1664, 1663, 1662, 1661, 1660, 1659, 1658, 1657, 1656, 1655, 1654, 1653, 1652, 1651, 1650, 1649, 1648, 1647, 1646, 1645, 1644, 1643, 1642, 1641, 1640, 1639, 1638, 1637, 1636, 1635, 1634, 1633, 1632, 1631, 1630, 1629, 1628, 1627, 1626, 1625, 1624, 1623, 1622, 1621, 1620, 1619, 1618, 1617, 1616, 1615, 1614, 1613, 1612, 1611, 1610, 1609, 1608, 1607, 1606, 1605, 1604, 1603, 1602, 1601, 1600, 1599, 1598, 1597, 1596, 1595, 1594, 1593, 1592, 1591, 1590, 1589, 1588, 1587, 1586, 1585, 1584, 1583, 1582, 1581, 1580, 1579, 1578, 1577, 1576, 1575, 1574, 1573, 1572, 1571, 1570, 1569, 1568, 1567, 1566, 1565, 1564, 1563, 1562, 1561, 1560, 1559, 1558, 1557, 1556, 1555, 1554, 1553, 1552, 1551, 1550, 1549, 1548, 1547, 1546, 1545, 1544, 1543, 1542, 1541, 1540, 1539, 1538, 1537, 1536, 1535, 1534, 1533, 1532, 1531, 1530, 1529, 1528, 1527, 1526, 1525, 1524, 1523, 1522, 1521, 1520, 1519, 1518, 1517, 1516, 1515, 1514, 1513, 1512, 1511, 1510, 1509, 1508, 1507, 1506, 1505, 1504, 1503, 1502, 1501, 1500, 1499, 1498, 1497, 1496, 1495, 1494, 1493, 1492, 1491, 1490, 1489, 1488, 1487, 1486, 1485, 1484, 1483, 1482, 1481, 1480, 1479, 1478, 1477, 1476, 1475, 1474, 1473, 1472, 1471, 1470, 1469, 1468, 1467, 1466, 1465, 1464, 1463, 1462, 1461, 1460, 1459, 1458, 1457, 1456, 1455, 1454, 1453, 1452, 1451, 1450, 1449, 1448, 1447, 1446, 1445, 1444, 1443, 1442, 1441, 1440, 1439, 1438, 1437, 1436, 1435, 1434, 1433, 1432, 1431, 1430, 1429, 1428, 1427, 1426, 1425, 1424, 1423, 1422, 1421, 1420, 1419, 1418, 1417, 1416, 1415, 1414, 1413, 1412, 1411, 1410, 1409, 1408, 1407, 1406, 1405, 1404, 1403, 1402, 1401, 1400, 1399, 1398, 1397, 1396, 1395, 1394, 1393, 1392, 1391, 1390, 1389,

[illegible]

voting rights, dividend rights, and other rights of a shareholder prior to exercise. The shares underlying the Warrant are subject to a lockup agreement for a period of six months after the closing of the IPO with respect to 12.5% of the shares issued and twelve months after the closing of the IPO for the remainder of the shares. In connection with the Termination Agreement, the Company agreed to register the resale of the shares of common stock underlying the Warrant upon a notice of 20 business days by the Warrant holder. X - ReferencesNo definition available.

+ Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(2\)\(g\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(2\)\(c\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(2\)\(e\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-1)Reference 10: <http://www.xbrl.org/2003/role/disclosureRef-Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContent>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef-Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1) + Details Name: us-gaap RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 6 - Subsequent Events 3 Months Ended Jun. 30, 2024 Notes to Financial Statements A Subsequent Events [Text Block] Note 6 â€” Subsequent Events A On July 10, 2024, we entered into a license agreement (the “Agreement”) with RF Innovations, Inc. (â€œRFI”), a privately held medical technology company, to license products utilizing RFIâ€™s intellectual property related to its Apex 6 Radiofrequency Generator (the “Licensed Products”). The Apex 6 Generator is a United States Food and Drug Administration (â€œFDA”) cleared ablation technology designed to lesion neural tissue for pain management in the peripheral nervous system. Pursuant to the Agreement, RFI granted us a perpetual non-exclusive worldwide royalty free fully paid license related to the Licensed Products, provided that the license did not include the right to sell certain products to customers for the treatment of spine pain. In connection with the Agreement, we issued RFI 250,000 unregistered shares of our common stock as consideration for the license. The Agreement provides RFI the right to terminate the license if we breach any representation, warranty or covenant contained in the Agreement, subject to any relevant cure periods, or if we are subject to a bankruptcy or insolvency event. A In July 2024, 3,594,000 warrants were exercised on a cashless basis resulting in a net share amount of 3,544,852 at an exercise price of \$0.01. X - ReferencesNo definition available. + Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContent>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2) + Details Name: us-gaap SubsequentEventsTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended Jun. 30, 2024 Insider Trading Arr Line Items A Material Terms of Trading Arrangement [Text Block] Item 5. Other Information A During the period covered by this Quarterly Report, none of the Companyâ€™s directors or executive officers has adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended). A Rule 10b5-1 Arrangement Adopted [Flag] false Non-Rule 10b5-1 Arrangement Adopted [Flag] false Rule 10b5-1 Arrangement Terminated [Flag] false Non-Rule 10b5-1 Arrangement Terminated [Flag] false X - ReferencesReference 1:

loss carryforwards. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is â€œmore likely than notâ€ that some component or all of the benefits of deferred tax assets will not be realized. Â The Company recorded no income tax provision for the three months ended June 30, 2024 and 2023, respectively. The effective tax rate for the three months ended June 30, 2024 and 2023 is zero. Â The Company estimates its annual effective tax rate at the end of each quarterly period. Jurisdictions with a projected loss for the year where a no tax benefit can be recognized due to the valuation allowance could result in a higher or lower effective tax rate during a particular quarter depending on the mix and timing of actual earnings versus annual projections. Â Share-Based Payment Arrangement [Policy Text Block] Stock-based Compensation Â Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. For awards with a performance condition, compensation expense is recognized over the requisite service period if it is probable that the performance condition will be satisfied. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the Company had paid cash for the goods or services. The Company estimates the fair value of options and equity classified warrants granted using an options pricing model. Expense is recognized within general and administrative expenses and forfeitures are recognized as they are incurred. Â Warrants, Policy [Policy Text Block] Warrants Â The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant's specific terms and applicable authoritative guidance in FASB ASC 480, Distinguishing Liabilities from Equity (â€œASC 480â€) and ASC 815, Derivatives and Hedging (â€œASC 815â€). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company's own ordinary shares and whether the warrant holders could potentially require a net cash settlement in a circumstance outside of the Company's control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Â For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing model or a Monte Carlo simulation. Â Earnings Per Share, Policy [Policy Text Block] Loss Per Common Share Â Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. Generally, the Company's outstanding warrants are non-participating securities as they are not entitled to non-forfeitable rights to dividends or dividend equivalents during the vesting term and have no obligation to fund losses. Â However, the warrants described in Note 5A are participating securities as they receive a right to dividends, but they are not obligated to fund losses. In periods of loss, since no income is allocated to these securities, the Company's use of the treasury stock method derives the same result. The dilutive effect of convertible securities is calculated using the if-converted method. Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted calculation for the entire period being presented. Â For the three months ended June 30, 2024 and 2023, dilutive securities that were not included in the calculations of the loss per common share because they would be anti-dilutive included the following: Â June 30, 2024 Â 2023 Â Equity based warrants to purchase common shares Â 5,344,569 Â 6,569,929 Â Convertible Notes - common shares Â 665,000 Â 665,000 Â Convertible Notes - equity-based warrants to purchase common shares Â 500,000 Â Stock options granted under Company's incentive plan Â 4,329,579 Â 933,600 Â Total potentially dilutive securities Â 10,839,148 Â 7,503,529 Â Research and Development Expense, Policy [Policy Text Block] Research and Development Costs Â Research and development costs are expensed as incurred. Â Advertising Cost [Policy Text Block] Advertising Â It is our policy to expense advertising costs as incurred. Advertising expenses are included within general and administrative expenses within the statement of operations. For the three months ended June 30, 2024 and 2023, the Company recorded less than \$0.1 million and \$0.1 million, respectively. Â Stockholders' Equity, Policy [Policy Text Block] Fair Value of Common Stock Â Prior to establishing a public market for the Company's common stock, the estimated fair value of the Company's common stock was determined by the Company's board of directors as of the date of each option grant, with input from management, considering the Company's most recently available third-party valuations of common stock, recent sales of common stock to third parties, and the Company's board of directors' assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. Â Jumpstart Our Business Startups (JOBS) Act Accounting Election Policy [Policy Text Block] JOBS Act Accounting Election Â The Company qualifies as an emerging growth company (â€œEGCâ€), as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). The JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company's financial statements with another public company which is neither an early-stage company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Â Segment Reporting, Policy [Policy Text Block] Segments Â The Company currently operates in one reportable segment based on management's view of its business for purposes of evaluating performance and making operating decisions. Based upon this business model, the Company's Chief Executive Officer, whom the Company has determined to be its chief operating decision-maker, reviews financial information as one operating segment. Â New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Â In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures," which requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The guidance is effective for the Company's fiscal years beginning after December 15, 2024, with early adoption permitted. The Company does not expect the adoption of this standard to have any material impact on its financial statements. Â The Company does not believe that any recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements. Â Reclassification, Comparability Adjustment [Policy Text Block] Correction of an Immaterial Error in the Prior Period Financial Statements Â During the fourth quarter of fiscal 2024 (March 31, 2024), the Company determined that the prior year financial statements had an error caused by an immaterial classification error of certain research and development expense in accordance with ASC 730 Research and Development Costs. As a result, certain prior year amounts have been revised for consistency with the current year presentation. The Company assessed the materiality of this change in presentation on prior period financial statements in accordance with SEC Staff Accounting Bulletin No. 99, "Materiality," (ASC Topic 250, Accounting Changes and Error Corrections). Based on this assessment, the Company concluded that these classification error corrections in its Statements of Operations are not material to any previously presented financial statements based upon overall considerations of both quantitative and qualitative factors. The corrections had no impact on the fiscal year 2023 Balance Sheet, Statements of Cash Flows, or Statement of Changes in Stockholders' Equity. Further, the immaterial corrections did not result in a change in operating losses, net loss, or basic or diluted earnings per share in the Income Statement. Â A summary of immaterial corrections reflecting the prior period impact to the Company's Statement of Operations, for the quarter ended June 30, 2023 is shown below (in thousands): Â As Revised Â June 30, 2023 Â Correction Â June 30, 2023 Â General and administrative expense Â \$523A Â \$(20A) \$503A Research and development expense Â \$348A Â \$20A Â \$368A Net Loss Â \$871A Â \$871A X - Definition Disclosure of accounting policy regarding the Jumpstart Our Business Startups Act (the "JOBS Act"). + ReferencesNo definition available. + Details Name: amix_JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyPolicyTextBlock Namespace Prefix: amix Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionIn reference to offering costs in the period. + ReferencesNo definition available. + Details Name: amix_OfferingCostsPolicyPolicyTextBlock Namespace Prefix: amix Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for related party transactions. + ReferencesNo definition available. + Details Name: amix_RelatedPartyTransactionsPolicyPolicyTextBlock Namespace Prefix: amix Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of the accounting policy for substantial doubt about the ability to continue as a going concern. + ReferencesNo definition available. + Details Name: amix_SubstantialDoubtAboutGoingConcernPolicyPolicyTextBlock Namespace Prefix: amix Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of Warrant related activity. + ReferencesNo definition available. + Details Name: amix_WarrantsPolicyPolicyTextBlock Namespace Prefix: amix Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for advertising cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 50 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 35 -Topic 720 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1 + Details Name: us-gaap_AdvertisingCostsPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/70-10-50-1 + Details Name: us-gaap_DebtPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1-Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1-Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for determining the fair value of financial instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1 + Details Name: us-gaap_FairValueOffFinancialInstrumentsPolicy Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20-Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-

gaap Data Type: dtr-types:textBlockItemPolicyTypeBalance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1 + Details Name: us-gaap ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemPolicyTypeBalance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for segment reporting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 36 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29 + Details Name: us-gaap SegmentReportingPolicyPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemPolicyTypeBalance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemPolicyTypeBalance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479698/946-235-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-1 + Details Name: us-gaap StockholdersEquityPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemPolicyTypeBalance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap UseOfEstimates Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemPolicyTypeBalance Type: na Period Type: duration XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables) 3 Months Ended June 30, 2024 Notes Tables A Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] A A June 30, A A 2024 A A 2023 A A A A A A A Equity based warrants to purchase common shares A A 5,344,569A A 6,569,929A Convertible Notes - common shares A A 665,000A A A Convertible Notes - equity-based warrants to purchase common shares A A 500,000A A A Stock options granted under Company's incentive plan A A 4,329,579A A 933,600A A A A A A Total potentially dilutive securities A A 10,839,148A A A 7,503,529A Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] A A A A A A A As Revised A A June 30, 2023 A A Correction A A June 30, 2024 A General and administrative expense A \$523A A \$(20)A \$503A Research and development expense A A 348A A A 20A A A 368A Net Loss A \$871A A \$A A \$871A X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic

Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt RestatementAxis=srt_ScenarioPreviouslyReportedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt RestatementAxis=srt_RestatementAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt RestatementAxis=amix_AsRevisedMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 2 - Convertible Notes Payable (Details Textual) \$ / shares in Units, \$ in Millions 3 Months Ended 10 Months Ended Jan. 26, 2024 USD (\$) shares Sep. 09, 2023 USD (\$) / shares shares Jun. 30, 2024 USD (\$) / shares shares Jun. 30, 2024 USD (\$) / shares Autonomix Medical, Inc [Member] A A A Subsidiary, Ownership Percentage, Noncontrolling Owner 4.99% A A A Bridge Financing Warrants in Connection with Convertible Notes [Member] A A A Warrants and Rights Outstanding, Term (Year) A 5 years A A Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares A 0.25 A A Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | \$ / shares A \$ 1 A A Class of Warrant or Right, Lock-up Agreement Term of Underlying Shares (Day) A 180 days A A Class of Warrant or Right, Percentage of Outstanding Stock A 25.00% A A Bridge Financing Warrants in Connection with Convertible Notes [Member] | Measurement Input, Price Volatility [Member] A A A Warrants and Rights Outstanding, Measurement Input A 1.0188 1.0188 Bridge Financing Warrants in Connection with Convertible Notes [Member] | Measurement Input, Expected Term [Member] A A A Warrants and Rights Outstanding, Measurement Input | yr A 5 5 Bridge Financing Warrants in Connection with Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member] A A A Warrants and Rights Outstanding, Measurement Input A 0.044 0.044 Bridge Financing Warrants in Connection with Convertible Notes [Member] | Measurement Input, Discount Rate [Member] A A A Warrants and Rights Outstanding, Measurement Input A 0.20 0.20 Bridge Financing Warrants in Connection with Convertible Notes [Member] | Measurement Input, Discount for Lack of Marketability [Member] A A A Warrants and Rights Outstanding, Measurement Input A 0.1577 0.1577 Conversion of Convertible Notes to Common Stock [Member] A A A Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares 335,000 A 335,000 A Maximum [Member] | Autonomix Medical, Inc [Member] A A A Subsidiary, Ownership Percentage, Noncontrolling Owner 4.99% A A A The Notes [Member] A A A A Proceeds from Convertible Debt A A A \$ 2.0 Debt Instrument, Interest Rate, Effective Percentage A A 15.30% 15.30% The Notes [Member] | Autonomix Medical, Inc [Member] A A A Subsidiary, Ownership Percentage, Noncontrolling Owner A 4.99% A A The Notes [Member] | Conversion of Convertible Notes to Common Stock [Member] A A A Debt Instrument, Convertible, Conversion Price (in dollars per share) | \$ / shares A 2 A A Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares A A 1,000,000 The Notes [Member] | Maximum [Member] A A A Debt Instrument, Face Amount A \$ 2.0 A A The Notes [Member] | Minimum [Member] A A A Interest Expense, Debt A A \$ 0.1 A Convertible Debt with 4.99% Beneficial Ownership Limitation [Member] A A A Convertible Notes Payable \$ 1.3 A A Debt Instrument, Convertible, Number of Equity Instruments 665,000 A A A X - DefinitionPertains to the term of the lock-up agreement associated with the shares underlying the warrants. + ReferencesNo definition available. + Details Name: amix_ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares Namespace Prefix: amix_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionRepresents the warrants as a proportion of outstanding capital stock. + ReferencesNo definition available. + Details Name: amix_ClassOfWarrantOrRightPercentageOfOutstandingStock Namespace Prefix: amix_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionIncluding the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap ConvertibleNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionThe number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6 + Details Name: us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItem Type Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instant X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity. + ReferencesNo definition available. + Details Name: us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionValue of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItem Type Balance Type: na Period Type: instant X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: instant X - Details Name: srt_OwnershipAxis=amix_AutonomixMedicalIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtConversionByUniqueDescriptionAxis=amix_ConversionOfConvertibleNotesToCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amix_TheNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 2 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) - USD (\$) in Thousands 3 Months Ended Jun. 30, 2024 Mar. 31, 2024 Net carrying amount \$ 1,043 \$ 1,002 The Notes [Member] | Convertible Debt [Member] Á Á Zero-coupon convertible notes payable due on December 31, 2025 1,330 Á Amortized debt discount 287 Á Net carrying amount \$ 1,043 Á X - DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name> Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2>: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4): <http://www.xbrl.org/2003/role/exampleRef-Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3): <http://www.xbrl.org/2003/role/exampleRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4>: <http://www.xbrl.org/2003/role/exampleRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5>: <http://www.xbrl.org/2003/role/disclosureRef-Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6>:

amix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonoptionEquityInstrumentsExecutedNumberOutstandingNumber Namespace Prefix: amix_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionRepresents the common shares refunded during the period. + ReferencesNo definition available. + Details Name: amix_StockRefundedDuringPeriodSharesCommonStock Namespace Prefix: amix_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1:

available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1:

(1)(i) - Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 2:

ment Options [Member] | Share-Based Payment Arrangement, Tranche Four [Member] | Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) 225,000 -A Employment Contracts [Member] | Executive Vice Chair and Strategic Advisor to the Chief Executive Officer [Member] -A Employment Agreement, Term of Contract (Year) 2 years -A Annual Base Salary | \$ 150,000 -A Employment Agreement, Bonus as a Percentage of Annual Base Compensation 50.00% -A Pending Litigation [Member] -A Loss Contingency, Pending Claims, Number 0 -X - Definition Represents the annual base salary. + ReferencesNo definition available. + Details Name: amix AnnualBaseSalary Namespace Prefix: amix Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCommitment made to pay an annual bonus expressed as a percentage of the individual's base salary. + ReferencesNo definition available. + Details Name: amix EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation Namespace Prefix: amix Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPertains to the terms of the employment agreement. + ReferencesNo definition available. + Details Name: amix EmploymentAgreementTermOfContract Namespace Prefix: amix Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for employee benefit and equity-based compensation. + ReferencesNo definition available. + Details Name: us-gaap EmployeeBenefitsAndShareBasedCompensation Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of pending claims pertaining to a loss contingency. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9) + Details Name: us-gaap LossContingencyPendingClaimsNumber Namespace Prefix: us-gaap Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDnThnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionFair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue1 Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap TypeOfArrangementAxis=us-gaap EmploymentContractsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt TitleOfIndividualAxis=srt ChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt StatementScenarioAxis=amix ScenarioContractTerminationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt StatementScenarioAxis=amix ScenarioContractTerminationWithoutCauseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap AwardTypeAxis=amix InducementOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap VestingAxis=us-gaap ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap VestingAxis=us-gaap ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap VestingAxis=us-gaap ShareBasedCompensationAwardTrancheThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap VestingAxis=amix ShareBasedPaymentArrangementTrancheFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt TitleOfIndividualAxis=amix ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap LitigationStatusAxis=us-gaap PendingLitigationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 5 - Related Party Transactions (Details Textual) - USD (\$) / shares in Units, \$ in Thousands 3 Months Ended Jan. 29, 2024 Jul. 07, 2023 Jun. 30, 2024 Jun. 30, 2023 Mar. 31, 2024 The Warrant [Member] | Termination Agreement [Member] -A -A -A -A Class of Warrant or Right, Value of Securities Called by Warrants or Rights \$ 8,000 -A -A -A Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \$ 0.001 -A -A -A Warrants and Rights Outstanding, Term (Year) 5 years -A -A -A Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 1,600,000 -A -A -A The Warrant [Member] | Termination Agreement [Member] | Common Stock, 6 Months Lock-up Period [Member] -A -A -A Class of Warrant or Right, Lock-up Agreement Term of Underlying Shares (Day) 6 months -A -A -A Class of Warrant or Right, Percentage of Outstanding Stock 12.50% 12.50% -A -A -A The Warrant [Member] | Termination Agreement [Member] | Common Stock, 12 Months Lock-up Period [Member] -A -A -A Class of Warrant or Right, Lock-up Agreement Term of Underlying Shares (Day) 12 months -A -A -A Management, Board of Director, and Family [Member] -A -A -A Related Party Transaction, Amounts of Transaction -A \$ 500 -A -A Management, Board of Director, and Family [Member] | The Bridge Offering [Member] -A -A -A Proceeds from Issuance of Debt -A \$ 0 -A -A Accounting and Financial Reporting Services [Member] | Chief Financial Officer [Member] -A -A -A Accounts Payable and Accrued Liabilities -A \$ 0 -A -A Accounting and Financial Reporting Services [Member] | Chief Financial Officer [Member] | Maximum [Member] -A -A -A Accounts Payable and Accrued Liabilities -A \$ 100 -A -A Management [Member] -A -A -A Related Party Transaction, Amounts of Transaction -A \$ 400 -A -A Related Party [Member] -A -A -A Related Party Transaction, Amounts of Transaction -A \$ 100 -A -X - DefinitionPertains to the term of the lock-up agreement associated with the shares underlying the warrants. + ReferencesNo definition available. + Details Name: amix ClassOfWarrantOrRightLockupAgreementTermOfUnderlyingShares Namespace Prefix: amix Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRepresents the warrants as a proportion of outstanding capital stock. + ReferencesNo definition available. + Details Name: amix ClassOfWarrantOrRightPercentageOfOutstandingStock Namespace Prefix: amix Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionValue of securities into which the class of warrant or right may be converted. + ReferencesNo definition available. + Details Name: amix ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: amix Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(15\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-50-15](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-50-15)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(15\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-50-15](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-50-15) + Details Name: us-gaap AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. + ReferencesReference 1:

[illegible]

[illegible]

```
report.reu { background-color: #def; }.report.reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report.ro, .report.rou { background-color: white; }.report.rou td { border-bottom: 1px solid black; }.report.rou table td, .report.rou table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report.fn { white-space: nowrap; } /* styles for numeric types */ .report.num, .report.nump { text-align: right; white-space: nowrap; }.report.nump { padding-left: 2em; }.report.nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report.text { text-align: left; white-space: normal; }.report.text.big { margin-bottom: 1em; width: 17em; }.report.text.more { display: none; }.report.text.note { font-style: italic; font-weight: bold; }.report.text.small { width: 10em; }.report.sup { font-style: italic; }.report.outterFootnotes { font-size: 1em; }.XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1.html 119 233 1 true 56 0 false 8 false false R1.htm 000 - Document - Document And Entity Information Sheet http://autonomix.com/20240630/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Balance Sheets (Unaudited) Sheet http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited- Condensed Balance Sheets (Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Balance Sheets (Unaudited) (Parentheticals) Sheet http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-parentheticals Condensed Balance Sheets (Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited- Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited) Sheet http://autonomix.com/20240630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited Condensed Statements of Changes in Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://autonomix.com/20240630/role/statement-condensed-statements-of-cash-flows-unaudited- Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies Sheet http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Convertible Notes Payable Notes http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable Note 2 - Convertible Notes Payable Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Equity Sheet http://autonomix.com/20240630/role/statement-note-3-equity Note 3 - Equity Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Commitments and Contingencies Sheet http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies Note 4 - Commitments and Contingencies Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Related Party Transactions Sheet http://autonomix.com/20240630/role/statement-note-5-related-party-transactions Note 5 - Related Party Transactions Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Subsequent Events Sheet http://autonomix.com/20240630/role/statement-note-6-subsequent-events Note 6 - Subsequent Events Notes 12 false false R13.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/ro/InsiderTradingArrangements Insider Trading Arrangements Notes 13 false false R14.htm 995458 - Disclosure - Significant Accounting Policies (Policies) Sheet http://autonomix.com/20240630/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies 14 false false R15.htm 995459 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables) Sheet http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables) Tables http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables 15 false false R16.htm 995460 - Disclosure - Note 2 - Convertible Notes Payable (Tables) Notes http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-tables Note 2 - Convertible Notes Payable (Tables) Tables http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable 16 false false R17.htm 995461 - Disclosure - Note 3 - Equity (Tables) Sheet http://autonomix.com/20240630/role/statement-note-3-equity-tables Note 3 - Equity (Tables) Tables http://autonomix.com/20240630/role/statement-note-3-equity 17 false false R18.htm 995462 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) Sheet http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) Details http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables 18 false false R19.htm 995463 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities (Details) Sheet http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-anti-dilutive-securities-details Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities (Details) Details 19 false false R20.htm 995464 - Disclosure - Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Prior Period Corrections (Details) Sheet http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-details Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Prior Period Corrections (Details) Details 20 false false R21.htm 995465 - Disclosure - Note 2 - Convertible Notes Payable (Details Textual) Notes http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-details-textual Note 2 - Convertible Notes Payable (Details Textual) Details http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-tables 21 false false R22.htm 995466 - Disclosure - Note 2 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) Notes http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-schedule-of-convertible-notes-payable-details Note 2 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) Details 22 false false R23.htm 995468 - Disclosure - Note 2 - Convertible Notes Payable - Schedule of Detachable Warrants (Details) Notes http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-details Note 2 - Convertible Notes Payable - Schedule of Detachable Warrants (Details) Details 23 false false R24.htm 995469 - Disclosure - Note 3 - Equity (Details Textual) Sheet http://autonomix.com/20240630/role/statement-note-3-equity-details-textual Note 3 - Equity (Details Textual) Details http://autonomix.com/20240630/role/statement-note-3-equity-tables 24 false false R25.htm 995470 - Disclosure - Note 3 - Equity - General and Administrative Expense (Details) Sheet http://autonomix.com/20240630/role/statement-note-3-equity-general-and-administrative-expense-details Note 3 - Equity - General and Administrative Expense (Details) Details 25 false false R26.htm 995471 - Disclosure - Note 3 - Equity - Restricted Stock Activity (Details) Sheet http://autonomix.com/20240630/role/statement-note-3-equity-restricted-stock-activity-details Note 3 - Equity - Restricted Stock Activity (Details) Details 26 false false R27.htm 995472 - Disclosure - Note 3 - Equity - Schedule of Stock Option Activity (Details) Sheet http://autonomix.com/20240630/role/statement-note-3-equity-schedule-of-stock-option-activity-details Note 3 - Equity - Schedule of Stock Option Activity (Details) Details 27 false false R28.htm 995473 - Disclosure - Note 3 - Equity - Schedule of Equity-Based Stock Warrants (Details) Sheet http://autonomix.com/20240630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-details Note 3 - Equity - Schedule of Equity-Based Stock Warrants (Details) Details 28 false false R29.htm 995474 - Disclosure - Note 4 - Commitments and Contingencies (Details Textual) Sheet http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies-details-textual Note 4 - Commitments and Contingencies (Details Textual) Details http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies 29 false false R30.htm 995475 - Disclosure - Note 5 - Related Party Transactions (Details Textual) Sheet http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual Note 5 - Related Party Transactions (Details Textual) Details http://autonomix.com/20240630/role/statement-note-5-related-party-transactions 30 false false R31.htm 995476 - Disclosure - Note 6 - Subsequent Events (Details Textual) Sheet http://autonomix.com/20240630/role/statement-note-6-subsequent-events-details-textual Note 6 - Subsequent Events (Details Textual) Details http://autonomix.com/20240630/role/statement-note-6-subsequent-events 31 false false All Reports Book All Reports amix-20240630.xsd amix-20240630_cal.xml amix-20240630_def.xml amix-20240630_lab.xml amix-20240630_pre.xml amix-20240630_10q.htm logo.jpg http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 51 MetaLinks.json IDEA: XBRL DOCUMENT 3 "version": "2.2", "instance": { "amix20240630_10q.htm": { "nsprefix": "amix", "nsuri": "http://autonomix.com/20240630", "dts": { "schema": { "local": { "amix-20240630.xsd" } }, "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" } }, "calculationLink": { "local": { "amix-20240630_cal.xml" } }, "definitionLink": { "local": { "amix-20240630_def.xml" } } }, "labelLink": { "local": { "amix-20240630_lab.xml" } }, "presentationLink": { "local": { "amix-20240630_pre.xml" } }, "inline": { "local": {
```


"html"], "reportCount": 1, "baseRef": "amix20240630_10q.htm", "first": true }, { "uniqueAnchor": { "contextRef": "i 2024-06-30 DebtInstrumentAxis- TheNotesMember_LongtermDebtTypeAxis-ConvertibleDebtMember", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "amix20240630_10q.htm", "unique": true }, { "R23": { "role": "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-details", "longName": "995468 - Disclosure - Note 2 - Convertible Notes Payable - Schedule of Detachable Warrants (Details)", "shortName": "Note 2 - Convertible Notes Payable - Schedule of Detachable Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "i 2024-03-31", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "amix20240630_10q.htm", "first": true }, { "uniqueAnchor": { "contextRef": "d 2024-04-01 2024-06-30", "name": "amix:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "amix20240630_10q.htm", "unique": true }, { "R24": { "role": "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual", "longName": "995469 - Disclosure - Note 3 - Equity (Details Textual)", "shortName": "Note 3 - Equity (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "d 2023-04-01 2023-06-30", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "amix20240630_10q.htm", "first": true }, { "uniqueAnchor": { "contextRef": "i 2023-11-29", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "amix20240630_10q.htm", "unique": true }, { "R25": { "role": "http://autonomix.com/20240630/role/statement-note-3-equity-general-and-administrative-expense-details", "longName": "995470 - Disclosure - Note 3 - Equity - General and Administrative Expense (Details)", "shortName": "Note 3 - Equity - General and Administrative Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "d 2024-04-01 2024-06-30 IncomeStatementLocationAxis- GeneralAndAdministrativeExpenseMember", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "amix20240630_10q.htm", "first": true }, { "uniqueAnchor": null }, { "R26": { "role": "http://autonomix.com/20240630/role/statement-note-3-equity-restricted-stock-activity-details", "longName": "995471 - Disclosure - Note 3 - Equity - Restricted Stock Activity (Details)", "shortName": "Note 3 - Equity - Restricted Stock Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "i 2024-06-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "amix20240630_10q.htm", "first": true, "unique": true }, { "uniqueAnchor": { "contextRef": "i 2024-06-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "amix20240630_10q.htm", "first": true, "unique": true }, { "R27": { "role": "http://autonomix.com/20240630/role/statement-note-3-equity-schedule-of-stock-option-activity-details", "longName": "995472 - Disclosure - Note 3 - Equity - Schedule of Stock Option Activity (Details)", "shortName": "Note 3 - Equity - Schedule of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "i 2024-03-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "amix20240630_10q.htm", "first": true }, { "uniqueAnchor": { "contextRef": "d 2024-04-01 2024-06-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "amix20240630_10q.htm", "unique": true }, { "R28": { "role": "http://autonomix.com/20240630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-details", "longName": "995473 - Disclosure - Note 3 - Equity - Schedule of Equity-Based Stock Warrants (Details)", "shortName": "Note 3 - Equity - Schedule of Equity-Based Stock Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "i 2024-03-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "amix20240630_10q.htm", "first": true }, { "uniqueAnchor": { "contextRef": "d 2024-04-01 2024-06-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "amix20240630_10q.htm", "unique": true }, { "R29": { "role": "http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies-details-textual", "longName": "995474 - Disclosure - Note 4 - Commitments and Contingencies (Details Textual)", "shortName": "Note 4 - Commitments and Contingencies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "d 2024-04-01 2024-06-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "amix20240630_10q.htm", "first": true }, { "uniqueAnchor": { "contextRef": "d 2024-04-01 2024-06-30 TypeOfArrangementAxis-EmploymentContractsMember", "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "amix20240630_10q.htm", "unique": true }, { "R30": { "role": "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual", "longName": "995475 - Disclosure - Note 5 - Related Party Transactions (Details Textual)", "shortName": "Note 5 - Related Party Transactions (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "d 2024-01-29 2024-01-29 ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember", "name": "amix:ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "amix20240630_10q.htm", "first": true, "unique": true }, { "uniqueAnchor": { "contextRef": "d 2024-01-29 2024-01-29 ClassOfWarrantOrRightAxis-TheWarrantMember_RelatedPartyTransactionAxis-TerminationAgreementMember", "name": "amix:ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "amix20240630_10q.htm", "first": true, "unique": true }, { "R31": { "role": "http://autonomix.com/20240630/role/statement-note-6-subsequent-events-details-textual", "longName": "995476 - Disclosure - Note 6 - Subsequent Events (Details Textual)", "shortName": "Note 6 - Subsequent Events (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "d 2024-07-10 2024-07-10 SubsequentEventTypeAxis-SubsequentEventMember_SubsidarySaleOfStockAxis-RfInnovationsIncMember", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "amix20240630_10q.htm", "first": true, "unique": true }, { "uniqueAnchor": { "contextRef": "d 2024-07-10 2024-07-10 SubsequentEventTypeAxis-SubsequentEventMember_SubsidarySaleOfStockAxis-RfInnovationsIncMember", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "amix20240630_10q.htm", "first": true, "unique": true }, { "tag": { "amix_AccountingAndFinancialReportingServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://autonomix.com/20240630", "localname": "AccountingAndFinancialReportingServicesMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-5-related-party-transactions", "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Accounting and Financial Reporting Services [Member]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "presentation": ["http://autonomix.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "terseLabel": "Accounts Payable and Accrued Liabilities", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations." } } }, "auth_ref": ["r86", "r87"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r39", "r516"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r41"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r51", "r516", "r647"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://autonomix.com/20240630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r414", "r556", "r557", "r558", "r561", "r621", "r648"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://autonomix.com/20240630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r33", "r34", "r261"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {

"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://autonomix.com/20240630/role/statement-condensed-
statements-of-cash-flows-unaudited-" }, "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities." } } }, "auth_ref": [] },
"us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingCostsPolicyTextBlock",
"presentation": { "http://autonomix.com/20240630/role/statement-significant-accounting-policies-policies" }, "lang": { "en-us": { "role": { "label": "Advertising Cost [Policy Text
Block]", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": ["r98"] }, "us-gaap_AdvertisingExpense": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": {
"http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" },
"lang": { "en-us": { "role": { "label": "us-gaap_AdvertisingExpense", "terseLabel": "Advertising Expense", "documentation": "Amount charged to advertising expense for the
period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": ["r298", "r508"] }, "us-
gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": { "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual",
"http://autonomix.com/20240630/role/statement-note-3-equity-general-and-administrative-expense-details" }, "lang": { "en-us": { "role": { "label": "us-
gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-
based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r291", "r296"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": { "http://autonomix.com/20240630/role/statement-document-and-entity-information" }, "lang": {
"en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } },
"auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation": { "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-schedule-of-
convertible-notes-payable-details" }, "lang": { "en-us": { "role": { "label": "Amortized debt discount", "documentation": "Amount of noncash expense included in interest
expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash
interest expense." } } }, "auth_ref": ["r3", "r60", "r235", "r629"] }, "amix_AnnualBaseSalary": { "xbrltype": "monetaryItemType", "nsuri": "http://autonomix.com/20240630",
"localname": "AnnualBaseSalary", "crdr": "debit", "presentation": { "http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies-details-textual" },
"lang": { "en-us": { "role": { "label": "amix_AnnualBaseSalary", "terseLabel": "Annual Base Salary", "documentation": "Represents the annual base salary." } } }, "auth_ref": [] },
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": { "http://autonomix.com/20240630/role/statement-note-1-
description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" }, "lang": { "en-us": { "role": {
"label": "Antidilutive securities (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute
basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS
or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r155"] }, "us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": {
"http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-
antidilutive-securities-details" }, "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } },
"auth_ref": ["r24"] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AntidilutiveSecuritiesNameDomain", "presentation": { "http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-
summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details" }, "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]",
"documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS
amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r24"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": {
"http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies", "http://autonomix.com/20240630/role/statement-note-4-commitments-and-
contingencies-details-textual" }, "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation":
"Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r319"] },
"amix_AsRevisedMember": { "xbrltype": "domainItemType", "nsuri": "http://autonomix.com/20240630", "localname": "AsRevisedMember", "presentation": {
"http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-
period-corrections-details" }, "lang": { "en-us": { "role": { "label": "As Revised [Member]", "documentation": "Final revision after prior period adjustment." } } }, "auth_ref": [] },
"us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": {
"http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-" }, "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": {
"http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-" }, "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "Total Assets",
"documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r84", "r96", "r112", "r128", "r158", "r160", "r175", "r176", "r182",
"r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r320", "r322", "r341", "r376", "r438", "r493", "r494", "r516", "r528", "r590", "r591", "r635"] }, "us-
gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": {
"http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-" }, "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "presentation": {
"http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-" }, "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total
current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r109", "r115", "r128", "r182",
"r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r320", "r322", "r341", "r516", "r590", "r591", "r635"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": { "http://autonomix.com/20240630/role/statement-condensed-
balance-sheets-unaudited-" }, "lang": { "en-us": { "role": { "label": "Current assets." } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-balance-
sheets-unaudited-" }, "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 }, "presentation": { "http://autonomix.com/20240630/role/statement-condensed-balance-
sheets-unaudited-" }, "lang": { "en-us": { "role": { "label": "us-gaap_AssetsNoncurrent", "totalLabel": "Total long term assets", "documentation": "Sum of the carrying amounts
as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } },
"auth_ref": ["r128", "r182", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r320", "r322", "r341", "r590", "r591", "r635"] }, "us-
gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": {
"http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-" }, "lang": { "en-us": { "role": { "label": "Long term assets." } } }, "auth_ref": [] },
"amix_AutonomixMedicalIncMember": { "xbrltype": "domainItemType", "nsuri": "http://autonomix.com/20240630", "localname": "AutonomixMedicalIncMember",
"presentation": { "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable", "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-
payable-details-textual", "http://autonomix.com/20240630/role/statement-note-3-equity", "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual" },
"lang": { "en-us": { "role": { "label": "Autonomix Medical, Inc [Member]", "documentation": "Name of entity in which ownership interest is disclosed." } } }, "auth_ref": [] },
"us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": {
"http://autonomix.com/20240630/role/statement-note-3-equity", "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual",
"http://autonomix.com/20240630/role/statement-note-3-equity-general-and-administrative-expense-details", "http://autonomix.com/20240630/role/statement-note-3-equity-
restricted-stock-activity-details", "http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies", "http://autonomix.com/20240630/role/statement-
note-4-commitments-and-contingencies-details-textual" }, "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under
share-based payment arrangement." } } }, "auth_ref": ["r262", "r263", "r264", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277",
"r278", "r279", "r280", "r281", "r282", "r283", "r286", "r287", "r288", "r289", "r290"] }, "us-gaap_BasisOfAccountingPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyTextBlock", "presentation": {
"http://autonomix.com/20240630/role/statement-significant-accounting-policies-policies" }, "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text
Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US
Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."} } }, "auth_ref": [] }, "amix_BlackscholesModelMember": { "xbrltype":
"domainItemType", "nsuri": "http://autonomix.com/20240630", "localname": "BlackscholesModelMember", "presentation": { "http://autonomix.com/20240630/role/statement-
note-3-equity", "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual" }, "lang": { "en-us": { "role": { "label": "Black-Scholes Model [Member]",
"documentation": "Black-Scholes-Merton used to estimate fair value of award under share-based payment arrangement." } } }, "auth_ref": [] },
"amix_BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://autonomix.com/20240630", "localname":
"BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember", "presentation": { "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable",
"http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-details-textual" }, "lang": { "en-us": { "role": { "label": "Bridge Financing Warrants in
Connection with Convertible Notes [Member]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [] }, "us-
gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-" },
"parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "presentation": { "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-"
"http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" },
"lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "terseLabel": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on
hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes
short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in
value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r16", "r111", "r486"] },
"us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashAndCashEquivalentsPolicyTextBlock", "presentation": { "http://autonomix.com/20240630/role/statement-significant-accounting-policies-policies" }, "lang": { "en-us": {
"role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy
for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash
and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts
(overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } },
"auth_ref": ["r17"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": {
"http://autonomix.com/20240630/role/statement-condensed-statements-of-cash-flows-unaudited-" }, "lang": { "en-us": { "role": { "label": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "Cash and cash
equivalents, at beginning of period", "periodEndLabel": "Cash and cash equivalents, at end of period", "documentation": "Amount of cash and cash equivalents, and cash
and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on
hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited
to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes
in value because of changes in interest rates." } } }, "auth_ref": ["r16", "r62", "r125"] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"crdr": "debit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-cash-flows-unaudited-" }, "parentTag": null, "weight": null, "order":

warrants as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "monetaryItemType", "nsuri": "http://autonomix.com/20240630/", "localname": "ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights", "crdr": "credit", "presentation": ["http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual"] }, "lang": { "en-us": { "role": { "label": "amix_ClassOfWarrantOrRightValueOfSecuritiesCalledByWarrantsOrRights", "documentation": "Value of securities into which the class of warrant or right may be converted." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited"] }, "lang": { "en-us": { "role": { "label": "Commitments and contingencies [Note 5]", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r47", "r89", "r378", "r425"] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies"] }, "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r68", "r196", "r197", "r482", "r581", "r586"] }, "amix_CommonStock12MonthsLockupPeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://autonomix.com/20240630/", "localname": "CommonStock12MonthsLockupPeriodMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-5-related-party-transactions"] }, "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual"] }, "lang": { "en-us": { "role": { "label": "Common Stock, 12 Months Lock-up Period [Member]", "documentation": "Pertains to the shares underlying the warrants." } } }, "auth_ref": [] }, "amix_CommonStock6MonthsLockupPeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://autonomix.com/20240630/", "localname": "CommonStock6MonthsLockupPeriodMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-5-related-party-transactions"] }, "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual"] }, "lang": { "en-us": { "role": { "label": "Common Stock, 6 Months Lock-up Period [Member]", "documentation": "Pertains to the shares underlying the warrants." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "CommonStockMember", "presentation": ["http://autonomix.com/20240630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited"] }, "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r518", "r519", "r520", "r522", "r523", "r524", "r525", "r556", "r557", "r561", "r621", "r646", "r648"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-parentheticals"] }, "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual"] }, "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r50"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "CommonStockSharesAuthorized", "presentation": ["http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-parentheticals"] }, "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual"] }, "lang": { "en-us": { "role": { "label": "Common stock, authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r50", "r426"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "CommonStockSharesIssued", "presentation": ["http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-parentheticals"] }, "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual"] }, "lang": { "en-us": { "role": { "label": "Common stock, issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r50"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "CommonStockSharesOutstanding", "presentation": ["http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-parentheticals"] }, "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual"] }, "lang": { "en-us": { "role": { "label": "Common stock, outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r8", "r50", "r426", "r444", "r648", "r649"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited"] }, "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual"] }, "lang": { "en-us": { "role": { "label": "Common stock, \$0.001 par value, 500,000,000 shares authorized as of June 30, 2024 and March 31, 2024, respectively, 19,242,081 and 18,846,094 shares issued and outstanding as of June 30, 2024 and March 31, 2024, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r50", "r380", "r516"] }, "amix_ConversionOfConvertibleNotesToCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://autonomix.com/20240630/", "localname": "ConversionOfConvertibleNotesToCommonStockMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable"] }, "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-details-textual": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-details-textual" } }, "http://autonomix.com/20240630/role/statement-note-3-equity": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual" } }, "lang": { "en-us": { "role": { "label": "Conversion of Convertible Notes to Common Stock [Member]", "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. 'Part noncash' refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "ConvertibleDebtMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-schedule-of-convertible-notes-payable-details"] }, "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-schedule-of-convertible-notes-payable-details-parentheticals": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-schedule-of-convertible-notes-payable-details-parentheticals" } }, "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": ["r70", "r214", "r215", "r225", "r226", "r227", "r231", "r232", "r233", "r234", "r235", "r498", "r499", "r500", "r501", "r502"] }, "us-gaap_ConvertibleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "ConvertibleDebtSecuritiesMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details"] }, "lang": { "en-us": { "role": { "label": "Convertible Debt Securities [Member]", "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder." } } }, "auth_ref": ["r593"] }, "us-gaap_ConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "ConvertibleDebtTableTextBlock", "presentation": ["http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-tables"] }, "lang": { "en-us": { "role": { "label": "Convertible Debt [Table Text Block]", "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount." } } }, "auth_ref": [] }, "amix_ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember": { "xbrltype": "domainItemType", "nsuri": "http://autonomix.com/20240630/", "localname": "ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable"] }, "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-details-textual": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-details-textual" } }, "http://autonomix.com/20240630/role/statement-note-3-equity": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual" } }, "lang": { "en-us": { "role": { "label": "Convertible Debt with 4.99% Beneficial Ownership Limitation [Member]", "documentation": "Information pertaining to the convertible debt." } } }, "auth_ref": [] }, "us-gaap_ConvertibleLongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "ConvertibleLongTermNotesPayable", "crdr": "credit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited"] }, "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-schedule-of-convertible-notes-payable-details": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-schedule-of-convertible-notes-payable-details" } }, "lang": { "en-us": { "role": { "label": "Net carrying amount", "documentation": "Long term debt - convertible notes, net of unamortized debt discount", "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": ["r13"] }, "us-gaap_ConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "ConvertibleNotesPayable", "crdr": "credit", "presentation": ["http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-details-textual"] }, "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual" } }, "lang": { "en-us": { "role": { "label": "us-gaap_ConvertibleNotesPayable", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": ["r13", "r88", "r644"] }, "amix_ConvertibleNotesToWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://autonomix.com/20240630/", "localname": "ConvertibleNotesToWarrantsMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details"] }, "lang": { "en-us": { "role": { "label": "Convertible Notes to Warrant [Member]", "documentation": "Represents convertible notes to warrants." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024/", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://autonomix.com/20240630/role/statement-document-and-entity-information"] }, "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "DebtConversionByUniqueDescriptionAxis", "presentation": ["http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable"] }, "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-details-textual": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-details-textual" } }, "http://autonomix.com/20240630/role/statement-note-3-equity": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual" } }, "lang": { "en-us": { "role": { "label": "Debt Conversion Description [Axis]", "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction." } } }, "auth_ref": ["r18", "r20"] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": ["http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-details-textual"] }, "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual" } }, "lang": { "en-us": { "role": { "label": "us-gaap_DebtConversionConvertedInstrumentSharesIssued1", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. 'Part noncash' refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": ["r18", "r20"] }, "us-gaap_DebtConversionNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "DebtConversionNameDomain", "presentation": ["http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable"] }, "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-details-textual": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-details-textual" } }, "http://autonomix.com/20240630/role/statement-note-3-equity": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual" } }, "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other

[illegible]

"amix_EmploymentAgreementBonusAsAPercentageOfAnnualBaseCompensation", "terseLabel": "Employment Agreement, Bonus as a Percentage of Annual Base Compensation", "documentation": "Commitment made to pay an annual bonus expressed as a percentage of the individual's base salary." } } }, "auth_ref": [] }, "amix_EmploymentAgreementTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://autonomix.com/20240630/", "localname": "EmploymentAgreementTermOfContract", "presentation": ["http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies-details-textual"] }, "lang": { "en-us": { "role": { "label": "amix_EmploymentAgreementTermOfContract", "terseLabel": "Employment Agreement, Term of Contract (Year)", "documentation": "Pertains to the terms of the employment agreement." } } }, "auth_ref": [] }, "us-gaap_EmploymentContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "EmploymentContractsMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies-details-textual"] }, "lang": { "en-us": { "role": { "label": "Employment Contracts [Member]", "documentation": "Contracts securing the services of employees, which may define the period of employment and the nature of the business relationship, and which may include nondisclosure and noncompete restrictions." } } }, "auth_ref": ["r35", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580"] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024/", "localname": "EntityAddressAddressLine1", "presentation": ["http://autonomix.com/20240630/role/statement-document-and-entity-information"] }, "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024/", "localname": "EntityAddressCityOrTown", "presentation": ["http://autonomix.com/20240630/role/statement-document-and-entity-information"] }, "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024/", "localname": "EntityAddressPostalZipCode", "presentation": ["http://autonomix.com/20240630/role/statement-document-and-entity-information"] }, "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024/", "localname": "EntityAddressStateOrProvince", "presentation": ["http://autonomix.com/20240630/role/statement-document-and-entity-information"] }, "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024/", "localname": "EntityCentralIndexKey", "presentation": ["http://autonomix.com/20240630/role/statement-document-and-entity-information"] }, "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r530"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024/", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://autonomix.com/20240630/role/statement-document-and-entity-information"] }, "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024/", "localname": "EntityCurrentReportingStatus", "presentation": ["http://autonomix.com/20240630/role/statement-document-and-entity-information"] }, "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024/", "localname": "EntityDomain", "presentation": ["http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-", "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-parentheticals", "http://autonomix.com/20240630/role/statement-condensed-statements-of-cash-flows-unaudited-", "http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited-", "http://autonomix.com/20240630/role/statement-document-and-entity-information"] }, "lang": { "en-us": { "role": { "label": "Entity Domain", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024/", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://autonomix.com/20240630/role/statement-document-and-entity-information"] }, "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024/", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://autonomix.com/20240630/role/statement-document-and-entity-information"] }, "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r536"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024/", "localname": "EntityRegistrantName", "presentation": ["http://autonomix.com/20240630/role/statement-document-and-entity-information"] }, "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r530"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024/", "localname": "EntityShellCompany", "presentation": ["http://autonomix.com/20240630/role/statement-document-and-entity-information"] }, "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r530"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024/", "localname": "EntitySmallBusiness", "presentation": ["http://autonomix.com/20240630/role/statement-document-and-entity-information"] }, "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r530"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024/", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://autonomix.com/20240630/role/statement-document-and-entity-information"] }, "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r530"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "EquityComponentDomain", "presentation": ["http://autonomix.com/20240630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited"] }, "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r8", "r106", "r119", "r120", "r121", "r132", "r133", "r134", "r136", "r142", "r145", "r147", "r159", "r183", "r186", "r187", "r255", "r309", "r310", "r312", "r313", "r314", "r316", "r317", "r318", "r324", "r325", "r326", "r327", "r328", "r329", "r332", "r342", "r343", "r344", "r345", "r346", "r347", "r352", "r354", "r357", "r388", "r395", "r396", "r397", "r414", "r466"] }, "amix_ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://autonomix.com/20240630/", "localname": "ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies-", "http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies-details-textual"] }, "lang": { "en-us": { "role": { "label": "Executive Vice Chair and Strategic Advisor to the Chief Executive Officer [Member]", "documentation": "Represents information pertaining to the executive vice chair and strategic advisor to the CEO." } } }, "auth_ref": [] }, "us-gaap_FairValueOffFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "FairValueOffFinancialInstrumentsPolicy", "presentation": ["http://autonomix.com/20240630/role/statement-significant-accounting-policies-policies"] }, "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": ["r7"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "GeneralAndAdministrativeExpense", "cldr": "debit", "calculation": ["http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited-", { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 }] }, "presentation": ["http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited-", "http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-details"] }, "lang": { "en-us": { "role": { "label": "General and administrative expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r58", "r448"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity", "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual", "http://autonomix.com/20240630/role/statement-note-3-equity-general-and-administrative-expense-details"] }, "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r58"] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "IPOMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity", "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual"] }, "lang": { "en-us": { "role": { "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "us-

gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited-": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited-": { "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Loss before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": { "r56", "r91", "r95", "r374", "r386", "r489", "r493", "r562", "r564", "r565", "r566", "r567" } }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": { "r188", "r194", "r195", "r338", "r339", "r340", "r392", "r394", "r451", "r485", "r510", "r645" } }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": { "http://autonomix.com/20240630/role/statement-note-3-equity", "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual", "http://autonomix.com/20240630/role/statement-note-3-equity-general-and-administrative-expense-details": { "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": { "r188", "r194", "r195", "r338", "r339", "r340", "r392", "r394", "r451", "r485", "r510", "r645" } }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": { "http://autonomix.com/20240630/role/statement-note-3-equity", "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual", "http://autonomix.com/20240630/role/statement-note-3-equity-general-and-administrative-expense-details": { "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": { "r194", "r195", "r338", "r339", "r340", "r392", "r394", "r451", "r485", "r510", "r645" } }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited-": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited-": { "lang": { "en-us": { "role": { "label": "Income taxes", "terseLabel": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": { "r97", "r105", "r146", "r147", "r158", "r166", "r176", "r303", "r304", "r311", "r390", "r509" } }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": { "http://autonomix.com/20240630/role/statement-significant-accounting-policies-policies": { "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": { "r118", "r301", "r302", "r305", "r306", "r307", "r308", "r408" } }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-cash-flows-unaudited-": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-cash-flows-unaudited-": { "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": { "r2" } }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-cash-flows-unaudited-": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-cash-flows-unaudited-": { "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities", "terseLabel": "Accrued expenses", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": { "r2" } }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "presentation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-cash-flows-unaudited-": { "lang": { "en-us": { "role": { "label": "Changes in operating assets - decrease/(increase):" } } }, "auth_ref": { "r2" } }, "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract", "presentation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-cash-flows-unaudited-": { "lang": { "en-us": { "role": { "label": "Changes in operating liabilities - (decrease)/increase:" } } }, "auth_ref": { "r2" } }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-cash-flows-unaudited-": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-cash-flows-unaudited-": { "lang": { "en-us": { "role": { "label": "Other current assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": { "r553" } }, "amix_InducementOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://autonomix.com/20240630", "localname": "InducementOptionsMember", "presentation": { "http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies-details-textual": { "lang": { "en-us": { "role": { "label": "Inducement Options [Member]", "documentation": "Represents information pertaining to inducement options." } } }, "auth_ref": { "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "auth_ref": { "r534" } }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": { "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-details-textual": { "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpenseDebt", "terseLabel": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": { "r60", "r233", "r240", "r501", "r502" } }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited-": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited-": { "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpenseNonoperating", "negatedLabel": "Interest expense", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": { "r164", "r551" } }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited-": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited-": { "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": { "r158", "r163", "r176", "r493", "r550" } }, "amix_JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630", "localname": "JumpstartOurBusinessStartupsJobsActAccountingElectionPolicyTextBlock", "presentation": { "http://autonomix.com/20240630/role/statement-significant-accounting-policies-policies": { "lang": { "en-us": { "role": { "label": "Jumpstart Our Business Startups (JOBS) Act Accounting Election Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding the Jumpstart Our Business Startups Act (the \u201cJOBS Act\u201d)." } } }, "auth_ref": { "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": { "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": { "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-": { "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": { "r13", "r40", "r41", "r42", "r45", "r46", "r47", "r48", "r128", "r182", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r321", "r322", "r323", "r341", "r424", "r488", "r528", "r590", "r635", "r636" } }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": { "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-": { "lang": { "en-us": { "role": { "label": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": { "r13", "r40", "r41", "r42", "r45", "r46", "r47", "r48", "r128", "r182", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r321", "r322", "r323", "r341", "r424", "r488", "r528", "r590", "r635", "r636" } }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": { "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-": { "lang": { "en-us": { "role": { "label": "Total long term liabilities", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": { "r13", "r45", "r46", "r47", "r48", "r128", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212",

"r322", "r323", "r341", "r590", "r635", "r636" }], "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": { "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-": { "lang": { "en-us": { "role": { "label": "Long term liabilities." } } }, "auth_ref": { "r41" } }, "us-gaap_LiabilityForUncertainTaxPositionsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUncertainTaxPositionsCurrent", "crdr": "credit", "presentation": { "http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual-": { "lang": { "en-us": { "role": { "label": "us-gaap_LiabilityForUncertainTaxPositionsCurrent", "terseLabel": "Liability for Uncertainty in Income Taxes, Current", "documentation": "Amount recognized for uncertainty in income taxes classified as current." } } }, "auth_ref": { "r41" } }, "us-gaap_LitigationStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusAxis", "presentation": { "http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies": { "lang": { "en-us": { "role": { "label": "Litigation Status [Axis]", "documentation": "Information by status of pending, threatened, or settled litigation." } } }, "auth_ref": { "r582", "r583", "r584", "r587" } }, "us-gaap_LitigationStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusDomain", "presentation": { "http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies": { "lang": { "en-us": { "role": { "label": "Litigation Status [Domain]", "documentation": "Status of pending, threatened, or settled litigation." } } }, "auth_ref": { "r582", "r583", "r584", "r587" } }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": { "http://autonomix.com/20240630/role/statement-document-and-entity-information-": { "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": { "r623", "r624", "r625", "r626" } }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": { "http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual-": { "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtFairValue", "terseLabel": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": { "r623", "r624", "r625", "r626" } }, "us-gaap_LongTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": { "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-schedule-of-convertible-notes-payable-details": { "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": { "r13", "r582", "r583", "r584" } }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": { "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-schedule-of-convertible-notes-payable-details": { "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": { "r13", "r29", "r582", "r583", "r584" } }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": { "http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies-details-textual-": { "lang": { "en-us": { "role": { "label": "us-gaap_LossContingencyPendingClaimsNumber", "terseLabel": "Loss Contingency, Pending Claims, Number", "documentation": "Number of pending claims pertaining to a loss contingency." } } }, "auth_ref": { "r588", "r589" } }, "amix_ManagementBoardOfDirectorFamilyMember": { "xbrltype": "domainItemType", "nsuri": "http://autonomix.com/20240630", "localname": "ManagementBoardOfDirectorFamilyMember", "presentation": { "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions": { "lang": { "en-us": { "role": { "label": "Management Board of Director and Family Member", "documentation": "Pertains to the related party." } } }, "auth_ref": { "r13", "r29", "r582", "r583", "r584" } }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": { "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual-": { "lang": { "en-us": { "role": { "label": "Management Board of Director and Family Member", "documentation": "Pertains to the related party." } } }, "auth_ref": { "r13", "r29", "r582", "r583", "r584" } }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": { "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual-": { "lang": { "en-us": { "role": { "label": "Management Board of Director and Family Member", "documentation": "Pertains to the related party." } } }, "auth_ref": { "r13", "r29", "r582", "r583", "r584" } }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": { "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual-": { "lang": { "en-us": { "role": { "label": "Management Board of Director and Family Member", "documentation": "Pertains to the related party." } } }, "auth_ref": { "r13", "r29", "r582", "r583", "r584" } }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": { "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual-": { "lang": { "en-us": { "role": { "label": "Management Board of Director and Family Member", "documentation": "Pertains to the related party." } } }, "auth_ref": { "r13", "r29", "r582", "r583", "r584" } }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": { "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual-": { "lang": { "en-us": { "role": { "label": "Management Board of Director and Family Member", "documentation": "Pertains to the related party." } } }, "auth_ref": { "r13", "r29", "r582", "r583", "r584" } }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": { "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual-": { "lang": { "en-us": { "role": { "label": "Management Board of Director and Family Member", "documentation": "Pertains to the related party." } } }, "auth_ref": { "r13", "r29", "r582", "r583", "r584" } }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": { "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual-": { "lang": { "en-us": { "role": { "label": "Management Board of Director and Family Member", "documentation": "Pertains to the related party." } } }, "auth_ref": { "r13", "r29", "r582", "r583", "r584" } }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": { "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual-": { "lang": { "en-us": { "role": { "label": "Management Board of Director and Family Member", "documentation": "Pertains to the related party." } } }, "auth_ref": { "r13", "r29", "r582", "r583", "r584" } }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": { "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual-": { "lang": { "en-us": { "role": { "label": "Management Board of Director and Family Member", "documentation": "Pertains to the related party." } } }, "auth_ref": { "r13", "r29", "r582", "r583", "r584" } }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": { "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual-": { "lang": { "en-us": { "role": { "label": "Management Board of Director and Family Member", "documentation": "Pertains to the related party." } } }, "auth_ref": { "r13", "r29", "r582", "r583", "r584" } }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": { "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual-": { "lang": { "en-us": { "role": { "label": "Management Board of Director and Family Member", "documentation": "Pertains to the related party." } } }, "auth_ref": { "r13", "r29", "r582", "r583", "r584" } }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": { "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual-": { "lang": { "en-us": { "role": { "label": "Management Board of Director and Family Member", "documentation": "Pertains to the related party." } } }, "auth_ref": { "r13", "r29", "r582", "r583", "r584" } }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": { "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual-": { "lang": { "en-us": { "role": { "label": "Management Board of Director and Family Member", "documentation": "Pertains to the related party." } } }, "auth_ref": { "r13", "r29", "r582", "r583", "r584" } }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossConting

```

CashFlowsProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-cash-flows-unaudited" },
"label": { "en-us": { "role": { "label": "Cash Flows from Operating Activities" } } }, "auth_ref": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-cash-flows-unaudited" },
"http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 }, "http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-cash-flows-unaudited" }, "http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited" }, "http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-details": { "en-us": { "role": { "label": "Net Loss", "terseLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net Loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": { "r57", "r64", "r92", "r108", "r116", "r117", "r121", "r128", "r135", "r137", "r138", "r140", "r141", "r142", "r146", "r147", "r151", "r182", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r315", "r318", "r334", "r341", "r387", "r446", "r464", "r465", "r526", "r590" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": { "http://autonomix.com/20240630/role/statement-significant-accounting-policies" }, "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": { "http://autonomix.com/20240630/role/statement-significant-accounting-policies" }, "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": { "r535" }, "ecd_NonRule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmtdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmtdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": { "r535" }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 }, "presentation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited" }, "lang": { "en-us": { "role": { "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total other income", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": { "r59" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited" }, "lang": { "en-us": { "role": { "label": "Other (expense) income" } } }, "auth_ref": { "http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual": { "xbrltype": "stringItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual", "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": { "r494", "r563" }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": { "http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" }, "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": { "r490", "r496", "r563" }, "amix_OfferingCostsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies", "lang": { "en-us": { "role": { "label": "Offering Costs, Policy [Policy Text Block]", "documentation": "In reference to offering costs in the period." } } }, "auth_ref": { "http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies": { "xbrltype": "stringItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies", "lang": { "en-us": { "role": { "label": "Operating Expenses", "crdr": "debit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 }, "presentation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited" }, "lang": { "en-us": { "role": { "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": { "http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies", "http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "presentation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited" }, "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": { "r95", "r489", "r562", "r564", "r565", "r566", "r567" }, "us-gaap_OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": { "http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies" }, "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": { "r38", "r65", "r66", "r83" }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 }, "presentation": { "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited" }, "lang": { "en-us": { "role": { "label": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": { "r114", "r516" }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": { "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-details-textual", "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-details-textual": { "xbrltype": "stringItemType", "nsuri": "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-details-textual", "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "auth_ref": { "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual", "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 }, "presentation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-cash-flows-unaudited" }, "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOf
```

and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": ["r518", "r519", "r522", "r523", "r524", "r525", "r646", "r648"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-parenteticals", "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual"] }, "lang": { "en-us": { "role": { "label": "Preferred stock, par value (in dollars per share)", "terseLabel": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r49", "r242"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-parenteticals", "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual"] }, "lang": { "en-us": { "role": { "label": "Preferred stock, authorized (in shares)", "terseLabel": "Preferred Stock, Shares Authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r49", "r426"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-parenteticals"] }, "lang": { "en-us": { "role": { "label": "Preferred stock, issued (in shares)", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r49", "r242"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-parenteticals"] }, "lang": { "en-us": { "role": { "label": "Preferred stock, outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r49", "r426", "r444", "r648", "r649"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-", "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual"] }, "lang": { "en-us": { "role": { "label": "Preferred stock, \$0.001 par value, 10,000,000 shares authorized as of June 30, 2024 and March 31, 2024, respectively, no shares issued and outstanding as of June 30, 2024 and March 31, 2024, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r49", "r379", "r516"] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": ["http://autonomix.com/20240630/role/statement-significant-accounting-policies-policies"] }, "lang": { "en-us": { "role": { "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": ["r549"] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity", "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual"] }, "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "presentation": ["http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-details-textual"] }, "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromConvertibleDebt", "terseLabel": "Proceeds from Convertible Debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": ["r14"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-cash-flows-unaudited-": { "parentTag": "us-gaap_NetCashProvidedByUseInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://autonomix.com/20240630/role/statement-condensed-statements-of-cash-flows-unaudited-", "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual"] }, "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock", "label": "us-gaap_ProceedsFromIssuanceOfCommonStock", "terseLabel": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r1"] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": ["http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual"] }, "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOfDebt", "terseLabel": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": ["r52"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited-", "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual"] }, "lang": { "en-us": { "role": { "label": "Fixed assets, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r4", "r355", "r375", "r385", "r516"] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": ["http://autonomix.com/20240630/role/statement-significant-accounting-policies-policies"] }, "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r4", "r101", "r104", "r384"] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": ["http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"] }, "lang": { "en-us": { "role": { "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable", "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-details-textual", "http://autonomix.com/20240630/role/statement-note-3-equity", "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual", "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions", "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual"] }, "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "auth_ref": ["r198", "r199", "r200", "r201", "r256", "r258", "r287", "r288", "r289", "r297", "r337", "r369", "r370", "r371", "r391", "r393", "r405", "r416", "r417", "r475", "r476", "r477", "r478", "r479", "r483", "r484", "r497", "r503", "r504", "r511", "r512", "r513", "r514", "r517", "r520", "r585", "r592", "r625", "r638", "r639", "r640", "r641", "r642"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable", "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-details-textual", "http://autonomix.com/20240630/role/statement-note-3-equity", "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual", "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions", "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual"] }, "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "auth_ref": ["r198", "r199", "r200", "r201", "r256", "r258", "r287", "r288", "r289", "r297", "r337", "r369", "r370", "r371", "r391", "r393", "r405", "r416", "r417", "r475", "r476", "r477", "r478", "r479", "r483", "r484", "r497", "r503", "r504", "r511", "r512", "r513", "r514", "r517", "r520", "r585", "r592", "r625", "r638", "r639", "r640", "r641", "r642"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://autonomix.com/20240630/role/statement-note-5-related-party-transactions", "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual"] }, "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r181", "r257", "r361", "r362", "r377", "r383", "r419", "r420", "r421", "r422", "r423", "r443", "r445", "r474"] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-5-related-party-transactions", "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual"] }, "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": ["r129", "r130", "r361", "r362", "r363", "r364", "r377", "r383", "r419", "r420", "r421", "r422", "r423", "r443", "r445", "r474"] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": ["http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual"] }, "lang": { "en-us": { "role": { "label": "us-gaap_RelatedPartyTransactionAmountsOfTransaction", "terseLabel": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": ["r37", "r361"] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": ["http://autonomix.com/20240630/role/statement-note-5-related-party-transactions", "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual"] }, "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": ["r361", "r362", "r634"] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": ["http://autonomix.com/20240630/role/statement-note-5-related-party-transactions", "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual"] }, "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://autonomix.com/20240630/role/statement-note-5-related-party-transactions", "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual"] }, "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r181", "r257", "r361", "r362", "r377", "r383", "r419", "r420", "r421", "r422", "r423", "r443", "r445", "r474", "r634"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://autonomix.com/20240630/role/statement-note-5-related-party-transactions", "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual"] }, "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r358", "r359", "r360", "r362", "r365", "r411", "r412", "r413", "r449", "r450", "r451", "r471", "r473"] }, "amix_RelatedPartyTransactionsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630", "localname": "RelatedPartyTransactionsPolicyTextBlock", "presentation": ["http://autonomix.com/20240630/role/statement-significant-accounting-policies-policies"] }, "lang": { "en-us": { "role": { "label": "Related Party Transactions Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for related party transactions." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited-": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited-", "http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-details"] }, "lang": { "en-us": { "role": { "label": "Research and development expense", "documentation": "Amount of expense for

research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r300", "r485", "r493", "r643"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity", "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://autonomix.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r299"] }, "srt_RestatementAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAdjustmentMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-details"], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Adjustment [Member]", "documentation": "Revision of Prior Period [Axis]" } } }, "auth_ref": ["r107", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r143", "r144", "r145", "r146", "r147", "r148", "r157", "r184", "r185", "r313", "r314", "r315", "r316", "r317", "r318", "r331", "r332", "r333", "r334", "r351", "r353", "r356", "r357", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r406", "r568"] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementDomain", "presentation": ["http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-details"], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]", "documentation": "Tabular disclosure of the general and administrative costs for restricted stock." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity", "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual", "http://autonomix.com/20240630/role/statement-note-3-equity-general-and-administrative-expense-details", "http://autonomix.com/20240630/role/statement-note-3-equity-restricted-stock-activity-details"], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": ["r24"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 }, "presentation": ["http://autonomix.com/20240630/role/statement-condensed-balance-sheets-unaudited", "http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "terseLabel": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r52", "r75", "r381", "r399", "r404", "r410", "r427", "r516"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://autonomix.com/20240630/role/statement-condensed-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r106", "r132", "r133", "r134", "r136", "r142", "r145", "r147", "r183", "r186", "r187", "r309", "r310", "r312", "r313", "r314", "r316", "r317", "r318", "r324", "r326", "r327", "r329", "r332", "r352", "r354", "r395", "r397", "r414", "r648"] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": ["http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap Revenues", "terseLabel": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r93", "r94", "r122", "r128", "r158", "r161", "r162", "r174", "r176", "r178", "r179", "r180", "r182", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r341", "r374", "r493", "r590"] }, "amix_RFInnovationsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://autonomix.com/20240630", "localname": "RFInnovationsIncMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-6-subsequent-events", "http://autonomix.com/20240630/role/statement-note-6-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "RF Innovations, Inc. [Member]", "documentation": "Represents information pertaining to RF Innovations, Inc." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]", "documentation": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r535"] }, "ecd_Rule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmtdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd Rule10b51ArrTrmtdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]", "documentation": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "amix_ScenarioContractTerminationMember": { "xbrltype": "domainItemType", "nsuri": "http://autonomix.com/20240630", "localname": "ScenarioContractTerminationMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies", "http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Scenario, Contract Termination [Member]", "documentation": "Information pertaining to the termination of the employment contract." } } }, "auth_ref": [] }, "amix_ScenarioContractTerminationWithoutCauseMember": { "xbrltype": "domainItemType", "nsuri": "http://autonomix.com/20240630", "localname": "ScenarioContractTerminationWithoutCauseMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies", "http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Scenario, Contract Termination, Without Cause [Member]", "documentation": "Information pertaining to contract termination." } } }, "auth_ref": [] }, "srt_ScenarioPreviouslyReportedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioPreviouslyReportedMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-details"], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]", "documentation": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r24"] }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "presentation": ["http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]", "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made." } } }, "auth_ref": ["r21", "r22", "r23"] }, "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]", "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award." } } }, "auth_ref": ["r81"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r11", "r12", "r76"] }, "us-gaap_ScheduleOfSharebasedRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSharebasedRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r31"] },

"presentation": "http://autonomix.com/20240630/role/statement-note-3-equity-schedule-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "Exercisable, options, weighted average exercise price (in dollars per share)", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } }, "auth_ref": ["r268"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity-schedule-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } }, "auth_ref": ["r273"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity-schedule-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } }, "auth_ref": ["r272"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity-details-textual", "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue", "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } }, "auth_ref": ["r280"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity-details-textual", "http://autonomix.com/20240630/role/statement-note-3-equity-schedule-of-stock-option-activity-details", "http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies-details-textual", "lang": { "en-us": { "role": { "label": "Granted, options (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } }, "auth_ref": ["r270"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity-schedule-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "Outstanding and exercisable, March 31, 2024", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } }, "auth_ref": ["r32"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity-details-textual", "http://autonomix.com/20240630/role/statement-note-3-equity-schedule-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "documentation": "Number of options outstanding, including both vested and non-vested options." } }, "auth_ref": ["r266", "r267"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity-details-textual", "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease", "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options." } }, "auth_ref": ["r600"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity-schedule-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "documentation": "Outstanding, options, weighted average exercise price (in dollars per share)", "periodStartLabel": "Outstanding, options, weighted average exercise price (in dollars per share)", "periodEndLabel": "Outstanding, options, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } }, "auth_ref": ["r266", "r267"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity-details-textual", "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity", "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual", "http://autonomix.com/20240630/role/statement-note-3-equity-general-and-administrative-expense-details", "http://autonomix.com/20240630/role/statement-note-3-equity-restricted-stock-activity-details", "http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies", "http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies-details-textual", "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } }, "auth_ref": ["r262", "r263", "r264", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r286", "r287", "r288", "r289", "r290"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity-schedule-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "Exercised, options, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } }, "auth_ref": ["r271"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity-schedule-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "Expired, options, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } }, "auth_ref": ["r273"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity-schedule-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "Forfeited/Cancelled, options, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } }, "auth_ref": ["r272"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity-details-textual", "http://autonomix.com/20240630/role/statement-note-3-equity-schedule-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "Granted, options, weighted average exercise price (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } }, "auth_ref": ["r270"] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies", "http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies-details-textual", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies", "http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies-details-textual", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://autonomix.com/20240630/role/statement-significant-accounting-policies", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } }, "auth_ref": ["r260", "r265", "r284", "r285", "r286", "r287", "r290", "r292", "r293", "r294", "r295"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity-schedule-of-equitybased-stock-warrants-details", "lang": { "en-us": { "role": { "label": "Outstanding, warrants, aggregate intrinsic value", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options." } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "presentation": [] }

"lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] },
"amix_SubstantialDoubtAboutGoingConcernPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630", "localname":
"SubstantialDoubtAboutGoingConcernPolicyTextBlock", "presentation": ["http://autonomix.com/20240630/role/statement-significant-accounting-policies-policies"] },
"lang": { "en-us": { "role": { "label": "Substantial Doubt About Going Concern Policy [Policy Text Block]", "documentation": "Disclosure of the accounting policy for substantial
doubt about the ability to continue as a going concern." } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "TableTextBlock", "presentation": ["http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-
summary-of-significant-accounting-policies-tables", "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-tables",
"http://autonomix.com/20240630/role/statement-note-3-equity-tables"] }, "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } },
"auth_ref": [] }, "amix_TerminationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://autonomix.com/20240630", "localname":
"TerminationAgreementMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-5-related-party-transactions",
"http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual"] }, "lang": { "en-us": { "role": { "label": "Termination Agreement [Member]",
"documentation": "Information by type of related party transaction." } } }, "auth_ref": [] }, "amix_The2023StockPlanMember": { "xbrltype": "domainItemType", "nsuri":
"http://autonomix.com/20240630", "localname": "The2023StockPlanMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity",
"http://autonomix.com/20240630/role/statement-note-3-equity-details-textual"] }, "lang": { "en-us": { "role": { "label": "The 2023 Stock Plan [Member]", "documentation": "Plan
name for share-based payment arrangement." } } }, "auth_ref": [] }, "amix_TheBridgeOfferingMember": { "xbrltype": "domainItemType", "nsuri":
"http://autonomix.com/20240630", "localname": "TheBridgeOfferingMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-5-related-party-
transactions", "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual"] }, "lang": { "en-us": { "role": { "label": "The Bridge Offering
[Member]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws
against credit facilities." } } }, "auth_ref": [] }, "amix_TheNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://autonomix.com/20240630", "localname":
"TheNotesMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable", "http://autonomix.com/20240630/role/statement-
note-2-convertible-notes-payable-details-textual", "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-schedule-of-convertible-notes-payable-
details", "http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-schedule-of-convertible-notes-payable-parenteticals"] }, "lang": { "en-us": { "role": { "label": "The Notes [Member]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } },
"auth_ref": [] }, "amix_TheWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://autonomix.com/20240630", "localname": "TheWarrantMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-5-related-party-transactions", "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-
details-textual"] }, "lang": { "en-us": { "role": { "label": "The Warrant [Member]", "documentation": "Information pertaining to warrants." } } }, "auth_ref": [] },
"srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies", "http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies-
details-textual", "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions", "http://autonomix.com/20240630/role/statement-note-5-
related-party-transactions-details-textual"] }, "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": ["r569", "r633"] },
"srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies",
"http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies-details-textual", "http://autonomix.com/20240630/role/statement-note-5-related-
party-transactions", "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual"] }, "lang": { "en-us": { "role": { "label": "Title and
Position [Domain]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol",
presentation": ["http://autonomix.com/20240630/role/statement-document-and-entity-information"] }, "lang": { "en-us": { "role": { "label": "Trading Symbol",
"documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://autonomix.com/20240630/role/statement-note-4-commitments-and-
contingencies", "http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies-details-textual"] }, "lang": { "en-us": { "role": { "label": "Collaborative
Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative
applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r319"] }, "us-gaap_UnderlyingAssetClassAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "UnderlyingAssetClassAxis", "presentation": ["http://autonomix.com/20240630/role/statement-note-5-related-party-transactions",
"http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual"] }, "lang": { "en-us": { "role": { "label": "Underlying Asset Class [Axis]",
"documentation": "Information by underlying asset class." } } }, "auth_ref": [] }, "us-gaap_UnderlyingAssetClassDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "UnderlyingAssetClassDomain", "presentation": ["http://autonomix.com/20240630/role/statement-note-5-related-party-
transactions", "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual"] }, "lang": { "en-us": { "role": { "label": "Underlying Asset
Class [Domain]", "documentation": "Major types of referenced/underlying asset classes (for example, corporate debt, sovereign debt, and structured finance)." } } },
"auth_ref": ["r36"] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://autonomix.com/20240630/role/statement-significant-accounting-policies-policies"] }, "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]",
"documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting
principles." } } }, "auth_ref": ["r26", "r27", "r28", "r99", "r100", "r102", "r103"] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueAxis", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity",
"http://autonomix.com/20240630/role/statement-note-3-equity-details-textual"] }, "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Axis]",
"documentation": "Information by valuation approach and technique." } } }, "auth_ref": ["r335", "r336", "r511", "r626"] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueDomain", "presentation": ["http://autonomix.com/20240630/role/statement-note-3-equity", "http://autonomix.com/20240630/role/statement-note-3-equity-
details-textual"] }, "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": ["r335", "r336", "r511", "r626"] }, "us-
gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": ["http://autonomix.com/20240630/role/statement-note-4-commitments-and-
contingencies-details-textual"] }, "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment
arrangement." } } }, "auth_ref": ["r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611",
"r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619"] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "VestingDomain", "presentation": ["http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies",
"http://autonomix.com/20240630/role/statement-note-4-commitments-and-contingencies-details-textual"] }, "lang": { "en-us": { "role": { "label": "Vesting [Domain]",
"documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601",
"r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619"] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details",
"http://autonomix.com/20240630/role/statement-note-3-equity", "http://autonomix.com/20240630/role/statement-note-3-equity-details-textual"] }, "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually
upon payment of a specified amount." } } }, "auth_ref": ["r518", "r519", "r522", "r523", "r524", "r525"] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": ["http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-details-textual"] }, "lang": { "en-us": { "role": { "label": "us-
gaap_WarrantsAndRightsOutstandingMeasurementInput", "terseLabel": "Warrants and Rights Outstanding, Measurement Input", "documentation": "Value of input used to
measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event
certain to occur." } } }, "auth_ref": ["r624", "r625", "r626"] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": ["http://autonomix.com/20240630/role/statement-note-2-convertible-notes-payable-details-
textual", "http://autonomix.com/20240630/role/statement-note-5-related-party-transactions-details-textual"] }, "lang": { "en-us": { "role": { "label": "us-
gaap_WarrantsAndRightsOutstandingTerm", "terseLabel": "Warrants and Rights Outstanding, Term (Year)", "documentation": "Period between issuance and expiration of
outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to
occur, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r624", "r625", "r626"] },
"amix_WarrantsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://autonomix.com/20240630", "localname": "WarrantsPolicyTextBlock",
presentation": ["http://autonomix.com/20240630/role/statement-significant-accounting-policies-policies"] }, "lang": { "en-us": { "role": { "label": "Warrants, Policy [Policy Text
Block]", "documentation": "Disclosure of Warrant related activity." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://autonomix.com/20240630/role/statement-condensed-statements-of-operations-unaudited"] }, "lang": { "en-us": { "role": { "label": "Weighted average shares
outstanding - basic and diluted (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares
or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in
that period." } } }, "auth_ref": ["r149", "r154"] }, "amix_WorkingCapitalDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://autonomix.com/20240630", "localname":
"WorkingCapitalDeficit", "crdr": "debit", "presentation": ["http://autonomix.com/20240630/role/statement-note-1-description-of-the-business-basis-of-presentation-and-
summary-of-significant-accounting-policies-details-textual"] }, "lang": { "en-us": { "role": { "label": "amix_WorkingCapitalDeficit", "terseLabel": "Working Capital (Deficit)",
"documentation": "Information pertaining to capital available to meet current, short-term obligations." } } }, "auth_ref": [] }, "amix_statement-statement-note-1-description-
of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-schedule-of-antidilutive-securities-details": { "xbrltype": "stringItemType", "nsuri":
"http://autonomix.com/20240630", "localname": "statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-
policies-schedule-of-antidilutive-securities-details", "lang": { "en-us": { "role": { "label": "Note 1 - Description of the Business, Basis of Presentation and Summary of
Significant Accounting Policies - Schedule of Anti-dilutive Securities (Details)" } } }, "auth_ref": [] }, "amix_statement-statement-note-1-description-of-the-business-basis-of-
presentation-and-summary-of-significant-accounting-policies-schedule-of-prior-period-corrections-details": { "xbrltype": "stringItemType", "nsuri":
"http://autonomix.com/20240630", "localname": "statement-statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-
policies-schedule-of-prior-period-corrections-details", "lang": { "en-us": { "role": { "label": "Note 1 - Description of the Business, Basis of Presentation and Summary of
Significant Accounting Policies - Schedule of Prior Period Corrections (Details)" } } }, "auth_ref": [] }, "amix_statement-statement-note-1-description-of-the-business-basis-of-
presentation-and-summary-of-significant-accounting-policies-tables": { "xbrltype": "stringItemType", "nsuri": "http://autonomix.com/20240630", "localname": "statement-
statement-note-1-description-of-the-business-basis-of-presentation-and-summary-of-significant-accounting-policies-tables", "lang": { "en-us": { "role": { "label": "Note 1 -
Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "amix_statement-statement-note-2-convertible-
notes-payable-schedule-of-convertible-notes-payable-details": { "xbrltype": "stringItemType", "nsuri": "http://autonomix.com/20240630", "localname": "statement-statement-
note-2-convertible-notes-payable-schedule-of-convertible-notes-payable-details", "lang": { "en-us": { "role": { "label": "Note 2 - Convertible Notes Payable - Schedule of
Convertible Notes Payable (Details)" } } }, "auth_ref": [] }, "amix_statement-statement-note-2-convertible-notes-payable-schedule-of-convertible-notes-payable-
parenteticals": { "xbrltype": "stringItemType", "nsuri": "http://autonomix.com/20240630", "localname": "statement-statement-note-2-convertible-notes-payable-schedule-of-
convertible-notes-payable-details-parenteticals", "lang": { "en-us": { "role": { "label": "Note 2 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details)
(Parenteticals)" } } }, "auth_ref": [] }, "amix_statement-statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-details": { "xbrltype": "stringItemType",
"nsuri": "http://autonomix.com/20240630", "localname": "statement-statement-note-2-convertible-notes-payable-schedule-of-detachable-warrants-details", "lang": { "en-us": { "role": { "label": "Note 2 - Convertible Notes Payable - Schedule of Detachable Warrants (Details)" } } }, "auth_ref": [] }, "amix_statement-statement-note-2-convertible-notes-
payable-tables": { "xbrltype": "stringItemType", "nsuri": "http://autonomix.com/20240630", "localname": "statement-statement-note-2-convertible-notes-payable-tables",
"lang": { "en-us": { "role": { "label": "Note 2 - Convertible Notes Payable" } } }, "auth_ref": [] }, "amix_statement-statement-note-3-equity-general-and-administrative-expense-
details": { "xbrltype": "stringItemType", "nsuri": "http://autonomix.com/20240630", "localname": "statement-statement-note-3-equity-general-and-administrative-expense-

[illegible]

[illegible]


```

"Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2", "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2", "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2", "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3", "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3", "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3", "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4", "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4", "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4", "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1", "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1", "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3", "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4", "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1", "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3", "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3", "ZIP 52.0001437749-24.026451-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24.026451-xbrl.zip M4SL!!0! (1;#5EG1)R(LOX %2L 1 86U6I>TR #<T #8S, YX M=7ZX+G&+2j;H G^<2Nj>JL=K?2JMI EVB8J4U2Z M2N+ H.D)S(NV)SNGR<?>0*9>E, #AQ<B/OS<+>L/LP>X>EYZ, @T(I(P M=7R7T, EYZJO @T(N V6006B+O)BLLU<J O?> KPJO<A<EF2&BVL M32C+>F97_@O?> UWF0L5/VNWQ>=>QZ, #GTW:W4IGLW7E\\#1=1*B=& /74 M< , \\2EP/G<CQ1 2.2PE6FGV>G.2A<O M82I2 M(IEl>=@S&ZJHAOD<.7A3GP6W8EG<-Y9W&>?HFLEBU33&N6SIRA<=>Q2O1Q<RH MG<V3I&ZK CP UJUV<2D<OSB6&+RH2/3<EC J29F100<X+POHOURX> Q**=>KQ MO7K<@<O'N29:B&Y+AVI<-, Q*<@NIKZY*P-109ER2< @BOYGI< MIK2H<QB 7T3CC<4CK<1JIOJ<3KIBNN54=U63871#D< , IJL<ZQA<+4<A0 M2J>U=2s1QBP<E>?>X2M0Y<=>ISSN6G(Y/A)Bj7XH-R<S&R<J4437U14C<S M->L(4.5VZ12<3DI<S<P<F<+>?>4<T@>8ZETVB=RI\\ VJ\\T(A27Z75<GJ4 M.J3.O)>#S4<=>9%G<XJ&EJ4 1IGY2B164EILY<K:PZ6SZZ< @JRM MZD 1 ) 45005RL7CJDII<S^>P3K<ZJ5O3A< , NH92E9P1 (+ (S7HC0A9I< MV\\M14I7&#D<#PI9D]MS27GD5F50? MI<OZEFU M3616M>K=>5LOW07MUD; 1.7M+Z/KGE6X1@<XIB<FHH5>^> MW*HYLTN<J9SIRYGD<+>S0+XYA<RU.R, 3S$6W<XH<EPBG79<4Y<INBES<X< M10Q6G<+>Z>=>1.7FKVSUIE<2FEI3P<#DN<9Q<+>A9A<S0LI?N0 M=>TDVZ<IT*J<3<VOYS NTL<D.VD*?R<E<O)>26#=>2BCD1D<+H<+I<+>N8.SX, M0-1R<OB-15< <6<Q03I>B>@<4<PUE>=>#1<80N9Q<J%D<#>XG&4X<K>?T(DI MISWB<P<RL+IB>2IRF8A<+>3GL<=>R2<SP<SCZ< @<@<4#Y<NE<A*#>H0US<K/PB<M0 >9>2)P0P<(K<60<D-8ECI08<@<ZRI48XUNCJ<L<SX<.<12D>S3K<=>374V9<+>33I,? JQX<U>=>+>S+> XU; L1F MVS<AR<SP1&E< , 322V.GMAOQWV<+>3<7.9<=>KYKN<4<@<DU3#1 XP9 , 9+7 MB<[E2GX07<?<K<R<S513JCYB< , *Y JZ<M<A7RISL2000<=>Z>=>NOOQFKGYZ< M'>1#<=>=<(>FSK72TGS<N>D9F<OGEFCYCO<1L>J39 <SS>M<T.ESEM<=>4 MKPEB5C<J.3RISPY>?>N>6>ORDYX<=> &YUK<8MGIV<+>=>W<VW<=>8H&(<\\> M2A<CUDP205<1, \\4W9<=>JHTV<4& 7K<#P.RG5%12IR7<7CK2V1K<6< , iZ=>G1<=>K<=>S9 , 9M<F<W=>=>JAI<ZUWO<H<S<E.B<F<J<GP: M1J>JG38H<H<I>DAIEH<JDIH4<=<K<I!L, 2<S<FHS<?>P<A<P<M1WRW<UO M8<S<OMF&Z<N<=<R<NIPQI<F<JDA18T<CNG3<G<FRS<BWR<L&IE5< , @52RH13T4 M=>\\5YY M12<B<BINIPZY<R<O762P<(MZ<N1<#>4I!LZ2U<R<LW16L<X, 8<BOZ<?>X<MVOY9<8AT<=>?>P<C<PKK<FCWU<P>J>S1>X2LFBX9<FC<?<7HC<(< M< <@<N0<=>1D<Y<Ds), 0#<1D6<UO<XYX94RIDV<231QZ<@<T1BW<+L1& 9219Y<+>(9UH M7TC10D<M0<@<EIJYX<@<C7<K
```


0001617867 us-gaap:RetainedEarningsMember 2024-06-30 0001617867 us-gaap:WarrantMember 2024-04-012024-06-30 0001617867 us-gaap:ConvertibleDebtSecuritiesMember 2023-04-012023-06-30 0001617867 us-gaap:ConvertibleDebtSecuritiesMember 2023-04-012023-06-30 0001617867 us-gaap:ConvertibleNotesToWarrantsMember 2024-04-012024-06-30 0001617867 amix:ConvertibleNotesToWarrantsMember 2023-04-012023-06-30 0001617867 us-gaap:EmployeeStockOptionMember 2024-04-012024-06-30 0001617867 us-gaap:EmployeeStockOptionMember 2023-04-012023-06-30 0001617867

srt:ScenarioPreviouslyReportedMember 2023-04-012023-06-30 0001617867 srt:RestatementAdjustmentMember 2023-04-012023-06-30 0001617867 amix:AsRevisedMember 2023-04-012023-06-30 0001617867 srt:MaximumMemberamix:TheNotesMember 2023-09-09 0001617867

amix:ConversionOfConvertibleNotesToCommonStockMemberamix:TheNotesMember 2023-09-09 0001617867

amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember 2023-09-09 0001617867

amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMember 2023-09-092023-09-09 0001617867 amix:AutonomixMedicalIncMemberamix:TheNotesMember 2023-09-09 0001617867 amix:TheNotesMember 2023-09-102024-06-30 0001617867 amix:ConversionOfConvertibleNotesToCommonStockMemberamix:TheNotesMember 2023-09-102024-06-30 0001617867 amix:TheNotesMember 2024-06-30 0001617867 amix:ConversionOfConvertibleNotesToCommonStockMember 2024-04-012024-06-30 0001617867 amix:AutonomixMedicalIncMembersrt:MaximumMember 2024-01-26 0001617867 amix:AutonomixMedicalIncMember 2024-01-26 0001617867

amix:ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember 2024-01-26 0001617867

amix:ConvertibleDebtWith499PercentBeneficialOwnershipLimitationMember 2024-01-262024-01-26 0001617867 amix:TheNotesMemberus-gaap:ConvertibleDebtMember 2024-06-30 0001617867 amix:TheNotesMemberus-gaap:ConvertibleDebtMember 2024-04-012024-06-30 0001617867

amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001617867

amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMemberus-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001617867

amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001617867

amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMemberus-gaap:MeasurementInputDiscountRateMember 2024-06-30 0001617867

amix:BridgeFinancingWarrantsInConnectionWithConvertibleNotesMemberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMember 2024-06-30 0001617867

srt:MinimumMemberamix:TheNotesMember 2024-04-012024-06-30 0001617867 2023-04-012024-03-31 0001617867 us-gaap:IPOMember 2024-01-262024-01-26 0001617867 us-gaap:IPOMember 2024-01-26 0001617867

us-gaap:IPOMember 2024-01-26 0001617867 amix:ConversionOfConvertibleNotesToCommonStockMember 2024-01-262024-01-26 0001617867 us-gaap:IPOMember 2024-05-132024-05-13 0001617867 2023-11-29 0001617867 us-gaap:RestrictedStockMember 2024-02-15 0001617867 us-gaap:RestrictedStockMemberus-gaap:GeneralAndAdministrativeExpenseMember 2024-04-012024-06-30 0001617867 us-gaap:RestrictedStockMemberus-gaap:GeneralAndAdministrativeExpenseMember 2023-04-012023-06-30 0001617867 us-gaap:RestrictedStockMember 2024-06-30 0001617867 us-gaap:RestrictedStockMember 2024-03-31 0001617867 us-gaap:RestrictedStockMember 2024-04-012024-06-30 0001617867 us-gaap:PrivatePlacementMember 2023-04-06 0001617867 us-gaap:PrivatePlacementMember 2024-04-012024-06-30 0001617867 amix:The2023StockPlanMember 2023-06-30 0001617867 amix:The2023StockPlanMember 2023-08-012023-08-31 0001617867 2024-04-012024-04-01 0001617867 amix:The2023StockPlanMember 2024-06-30 0001617867 amix:The2023StockPlanMember 2024-04-012024-06-30 0001617867 us-gaap:EmployeeStockOptionMemberamix:The2023StockPlanMember 2024-04-012024-06-30 0001617867 us-gaap:EmployeeStockOptionMemberamix:BlackscholesModelMember 2024-04-012024-06-30 0001617867 srt:MinimumMemberus-gaap:EmployeeStockOptionMemberamix:BlackscholesModelMember 2024-04-012024-06-30 0001617867 srt:MaximumMemberus-gaap:EmployeeStockOptionMemberamix:BlackscholesModelMember 2024-04-012024-06-30 0001617867 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-012024-06-30 0001617867 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-012024-06-30 0001617867 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-012023-06-30 0001617867 us-gaap:WarrantMember 2024-06-30 0001617867 us-gaap:WarrantMember 2024-04-012024-06-30 0001617867 us-gaap:WarrantMember 2023-04-012023-06-30 0001617867 us-gaap:PendingLitigationMember 2024-06-30 0001617867 us-gaap:EmploymentContractsMember 2024-04-012024-06-30 0001617867

srt:ChiefExecutiveOfficerMemberus-gaap:EmploymentContractsMember 2024-06-172024-06-17 0001617867

srt:ChiefExecutiveOfficerMemberamix:InducementOptionsMemberus-gaap:EmploymentContractsMember 2024-06-172024-06-17 0001617867

srt:ChiefExecutiveOfficerMemberamix:InducementOptionsMemberus-gaap:EmploymentContractsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-06-172024-06-17 0001617867 srt:ChiefExecutiveOfficerMemberamix:InducementOptionsMemberus-gaap:EmploymentContractsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-06-172024-06-17 0001617867 srt:ChiefExecutiveOfficerMemberamix:InducementOptionsMemberus-gaap:EmploymentContractsMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-06-172024-06-17 0001617867

srt:ChiefExecutiveOfficerMemberamix:InducementOptionsMemberus-gaap:EmploymentContractsMemberamix:SharebasedPaymentArrangementTrancheFourMember 2024-06-172024-06-17 0001617867 amix:ScenarioContractTerminationMembersrt:ChiefExecutiveOfficerMemberus-gaap:EmploymentContractsMember 2024-06-172024-06-17 0001617867 amix:ScenarioContractTerminationWithoutCauseMembersrt:ChiefExecutiveOfficerMemberus-gaap:EmploymentContractsMember 2024-06-172024-06-17 0001617867 amix:ExecutiveViceChairAndStrategicAdvisorToTheChiefExecutiveOfficerMemberus-gaap:EmploymentContractsMember 2024-06-172024-06-17 0001617867

amix:TheBridgeOfferingMemberamix:ManagementBoardOfDirectorFamilyMember 2024-04-012024-06-30 0001617867

amix:TheBridgeOfferingMemberamix:ManagementBoardOfDirectorFamilyMember 2023-04-012023-06-30 0001617867

srt:ChiefFinancialOfficerMemberamix:AccountingAndFinancialReportingServicesMember 2024-06-30 0001617867

srt:MaximumMembersrt:ChiefFinancialOfficerMemberamix:AccountingAndFinancialReportingServicesMember 2024-03-31 0001617867

amix:ManagementBoardOfDirectorFamilyMember 2024-04-012024-06-30 0001617867 srt:ManagementMember 2024-04-012024-06-30 0001617867 us-gaap:RelatedPartyMember 2024-04-012024-06-30 0001617867 amix:TheWarrantMemberamix:TerminationAgreementMember 2024-01-292024-01-29 0001617867

amix:TheWarrantMemberamix:TerminationAgreementMember 2023-07-07 0001617867

amix:TheWarrantMemberamix:TerminationAgreementMemberamix:CommonStock6MonthsLockupPeriodMember 2023-07-072023-07-07 0001617867

amix:TheWarrantMemberamix:TerminationAgreementMemberamix:CommonStock12MonthsLockupPeriodMember 2023-07-072023-07-07 0001617867

amix:TheWarrantMemberamix:TerminationAgreementMember 2024-01-29 0001617867

amix:TheWarrantMemberamix:TerminationAgreementMemberamix:CommonStock6MonthsLockupPeriodMember 2024-01-292024-01-29 0001617867 us-gaap:SubsequentEventMemberamix:RfInnovationsIncMember 2024-07-102024-07-10 0001617867 us-gaap:SubsequentEventMemberamix:RfInnovationsIncMember 2024-07-012024-07-30 0001617867 us-gaap:SubsequentEventMemberamix:RfInnovationsIncMember 2024-07-30 shares thunderdome:item iso4217:USD iso4217:USD shares utr:Y pure utr:D utr:M0001617867Autonomix Medical, Inc.f-0031012024

0.0010.001100000000100000000000.0010.0015000000000500000000192420811924208118

[illegible]

[illegible]

[illegible]

determine the fair value could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values are the probability weighting of the different settlement outcomes used.

The Company did not have any assets or liabilities measured at fair value as of or during the three-month period ending June 30, 2024 and March 31, 2024. There were not any transfers into or out of Level <em style="font: inherit;">3 as of June 30, 2024 and March 31, 2024.

The carrying value of short-term instruments, including cash, accounts payable and accrued expenses, approximate fair value due to the relatively short period to maturity for these instruments.

The Company determined that the estimated fair value of debt was approximately \$1.0 million. The fair value of debt was estimated using market rates the Company believes would be available for similar types of financial instruments and represents a Level <em style="font: inherit;">2 measurement.

The Company follows Accounting Standards Codification ("ASC") <em style="font: inherit;">850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions. See further discussion in Note <em style="font: inherit;">5 below on this matter.

The Company accounts for uncertain tax positions in accordance with the provisions of ASC <em style="font: inherit;">740, which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than not to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates. As of June 30, 2024 and March 31, 2024, the Company had no uncertain tax positions.

The Company does not expect to pay any significant federal, state, or foreign income taxes in our fiscal year <em style="font: inherit;">2025 (ending <em style="font: inherit;">March 31, 2025) as a result of the losses recorded during the three months ended June 30, 2024 and the additional losses expected for the remainder of our fiscal year <em style="font: inherit;">2025 and cumulative net operating loss carryforwards. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is "more likely than not" that some component or all of the benefits of deferred tax assets will not be realized.

The Company records a "sec-ix-hidden:c116052249" income tax provision for the three months ended June 30, 2024 and <em style="font: inherit;">2023, respectively. The effective tax rate for the three months ended June 30, 2024 and <em style="font: inherit;">2023 is zero. The Company estimates its annual effective tax rate at the end of each quarterly period. Jurisdictions with a projected loss for the year where the tax benefit can be recognized due to the valuation allowance could result in a higher or lower effective tax rate during a particular quarter depending on the mix and timing of actual earnings versus annual projections.

Warrants

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant's specific terms and applicable authoritative guidance in FASB ASC <em style="font: inherit;">480, Distinguishing Liabilities from Equity ("ASC <em style="font: inherit;">480") and ASC <em style="font: inherit;">815, Derivatives and Hedging ("ASC <em style="font: inherit;">815"). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC <em style="font: inherit;">480, meet the definition of a liability pursuant to ASC <em style="font: inherit;">480, and whether the warrants meet all of the requirements for equity classification under ASC <em style="font: inherit;">815, including whether the warrants are indexed to the Company's own ordinary shares and whether the warrant holders could potentially require "net cash settlement" in a circumstance outside of the Company's control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing model or a Monte Carlo simulation.

Loss Per Common Share

Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. Generally, the Company's outstanding warrants are non-participating securities as they are not entitled to non-forfeitable rights to dividends or dividend equivalents during the vesting term and have no obligation to fund losses.

However, the warrants described in Note <em style="font: inherit;">5 are participating securities as they receive a right to dividends, but they are not obligated to fund losses. In periods of loss, since income is allocated to these securities, the Company's use of the treasury stock method derives the same result. The dilutive effect of convertible securities is calculated using the "if-converted method." Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted calculation for the entire period being presented.

For the three months ended June 30, 2024 and <em style="font: inherit;">2023, dilutive securities that were included in the calculations of the loss per common share because they would be anti-dilutive included the following:

	June 30, 2024	March 31, 2024
Basic loss per common share	6,569,929	6,569,929
Diluted loss per common share	6,569,929	6,569,929

[illegible]

[illegible]

The Company utilized a Monte Carlo simulation model to determine the fair value of each Bridge Offering Warrant. The key inputs to the Monte Carlo simulation used to determine the fair value of each warrant include, the Company's stock price fair value which was determined through a back solve calculation such that the stock price results in the average total value of the Notes and the Bridge Offering Warrants being equal to the cash proceeds received, volatility based on a selection of publicly held peer companies of 101.88%, expected term of 5 years, risk free rate of 4.40%, discount rate of 20.00% and a discount for lack of marketability of 15.77%.</p>
<p style='font-family:'Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;'><p><p style='font-family:'Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;'>During the <em style='font: inherit;'>three months ended <em style='font: inherit;'>June 30, 2024, the Company recorded less than \$0.1 million in interest expense related to the amortization of the debt discount.</p>
<p style='font-family:'Times New Roman,' Times, serif; font-size: 10pt; margin: 0pt; text-align: left'><p><p style='font-family:'Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;'>The following table presents a summary of activity for the warrants issued in connection with the Company's Notes:</p>
<table border=

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

variant:normal;margin:0pt;"><p> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;text-indent: 18pt;">The Company utilizes a consulting firm that is owned by the Company's former Chief Financial Officer to provide accounting and financial reporting services and pays certain expenses on behalf of the Company. During the <em style="font: inherit;">three months ended <em style="font: inherit;">June 30, 2024 and <em style="font: inherit;">2023, the Company incurred fees of \$0 and less than \$0.1 million, respectively, for these services, excluding officer compensation. As of <em style="font: inherit;">June 30, 2024 and <em style="font: inherit;">March 31, 2024, the Company owed the consulting firm \$0 and less than \$0.1 million, respectively, for services and expenses.</p><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;text-indent: 18pt;">As of <em style="font: inherit;">June 30, 2024, members of the Company's management/Board and an immediate family member of the Company's management (related party), collectively purchased \$0.5 million (\$0.4 million and \$0.1 million, respectively) of the Bridge Offering.</p><p style="font-family: 'Times New Roman', font-size: 10pt;font-variant:normal;margin:0pt;"><p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">On <em style="font: inherit;">December 21, 2021,the Company entered into a perpetual worldwide, exclusive license agreement (the "License" or "License Agreement") with a company controlled by a significant stockholder of the Company (the "Licensee"). The License allows the Licensee to use certain intellectual property and technology related to the diagnosis and treatment of cardiovascular conditions held by the Company. Upon <em style="font: inherit;">90 days following the completion of an initial public offering or special purpose acquisition company transaction, the Licensee <em style="font: inherit;">may enter into sublicenses of the licensed intellectual property and technology.</p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"><p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">On <em style="font: inherit;">July 7, 2023,the Company and the Licensee entered into an Exclusive License Termination Agreement (the "Termination Agreement") in exchange for the issuance, upon the closing of the Company's initial public offering within <em style="font: inherit;">one year of the agreement's execution, of a warrant to purchase shares of the Company for a variable number of shares. The variable number of shares issued was based upon a fixed value of \$8.0 million divided by the price per share in the offering. The warrants are exercisable at a price of \$0.001 per share and <em style="font: inherit;">may be exercised any time after the issuance date, subject to a beneficial ownership limitation, and expires five years from the original issuance. The warrants provide voting rights, dividend rights, and other rights of a shareholder prior to exercise. The shares underlying the warrant will be subject to a lockup agreement for a period of six months after the closing of the offering with respect to 12.5% of the shares issued and twelve months after the closing of the offering for the remainder of the shares.</p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"><p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">On <em style="font: inherit;">January 29, 2024,we issued a warrant to purchase 1,600,000 shares (the "Warrant") pursuant to the Termination Agreement with Impulse Medical, Inc. ("Impulse")</i>.</i>The warrants are exercisable at a price of \$0.001 per share and <em style="font: inherit;">may be exercised any time after the issuance date, subject to a beneficial ownership limitation, and expires five years from the original issuance. The warrants provide voting rights, dividend rights, and other rights of a shareholder prior to exercise. The shares underlying the Warrant are subject to a lockup agreement for a period of <em style="font: inherit;">six months after the closing of the IPO with respect to 12.5% of the shares issued and <em style="font: inherit;">twelve months after the closing of the IPO for the remainder of the shares. In connection with the Termination Agreement, the Company agreed to register the resale of the shares of common stock underlying the Warrant upon a notice of <em style="font: inherit;">20 business days by the Warrant holder.</p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"><p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Note<em style="font: inherit;">6 Subsequent Events</p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">On <em style="font: inherit;">July 10, 2024,we entered into a license agreement (the "Agreement") with RF Innovations, Inc. ("RFI"), a privately held medical technology company, to license products utilizing RFI's intellectual property related to its Apex <em style="font: inherit;">6 Radiofrequency Generator (the "Licensed Products"). The Apex <em style="font: inherit;">6 Generator is a United States Food and Drug Administration ("FDA") cleared ablation technology designed to lesion neural tissue for pain management in the peripheral nervous system. Pursuant to the Agreement, RFI granted us a perpetual non-exclusive worldwide royalty free fully paid license related to the Licensed Products, provided that the license did <em style="font: inherit;">not include the right to sell certain products to customers for the treatment of spine pain. In connection with the Agreement, we issued RFI 250,000 unregistered shares of our common stock as consideration for the license. The Agreement provides RFI the right to terminate the license if we breach any representation, warranty or covenant contained in the Agreement, subject to any relevant cure periods, or if we are subject to a bankruptcy or insolvency event.</p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"><p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In <em style="font: inherit;">July 2024,we issued 3,594,000 warrants were exercised on a cashless basis resulting in a net share amount of 3,544,852 at an exercise price of \$0.01.</p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"><p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Other Information</p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;text-indent: 18pt;">During the period covered by this Quarterly Report, vertical-align: top;width: 48.1%;<p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Item 5</p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Other Information</p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;text-indent: 18pt;"><p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;text-indent: 18pt;">During the period covered by this Quarterly Report, vertical-align: top;width: 48.1%;<p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Item 5</p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Other Information</p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;text-indent: 18pt;"><p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;text-indent: 18pt;">During the period covered by this Quarterly Report, vertical-align: top;width: 48.1%;<p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Item 5</p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Other Information</p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;text-indent: 18pt;"><p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;text-indent: 18pt;">During the period covered by this Quarterly Report, vertical-align: top;width: 48.1%;<p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Item 5</p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Other Information</p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;text-indent: 18pt;"><p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;text-indent: 18pt;">During the period covered by this Quarterly Report, vertical-align: top;width: 48.1%;<p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Item 5</p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Other Information</p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;text-indent: 18pt;"><p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;text-indent: 18pt;">During the period covered by this Quarterly Report, vertical-align: top;width: 48.1%;<p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Item 5</p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Other Information</p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;text-indent: 18pt;"><p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;text-indent: 18pt;">During the period covered by this Quarterly Report, vertical-align: top;width: 48.1%;